-DOCSTART- -X- -X- -X- O

A	O
64 B-Age
year I-Age
old E-Age
female	O
known	O
for	O
HHT S-Disease_disorder
is	O
referred	O
to	O
our	O
clinic S-Nonbiological_location
for	O
recurrent S-Detailed_description
epistaxis S-Sign_symptom
for	O
nearly B-Duration
50 I-Duration
years E-Duration
.	O

She	O
has	O
had	O
recurrent	O
symptoms	O
since	O
the	O
age	O
of	O
16	O
when	O
her	O
condition	O
was	O
diagnosed	O
.	O

All	O
three	O
of	O
her	O
siblings	O
also	O
were	O
diagnosed	O
with	O
HHT	O
and	O
her	O
mother	O
passed	O
away	O
from	O
an	O
intracranial	O
hemorrhage	O
.	O

Eight	O
years	O
prior	O
to	O
presentation	O
she	O
had	O
undergone	O
a	O
left B-Detailed_description
- I-Detailed_description
sided E-Detailed_description
septodermoplasty S-Therapeutic_procedure
via	O
a	O
lateral S-Detailed_description
rhinotomy S-Therapeutic_procedure
approach	O
.	O

This	O
operation	O
had	O
significantly	O
reduced	O
the	O
frequency	O
of	O
her	O
symptoms S-Sign_symptom
and	O
for B-Duration
several I-Duration
years E-Duration
her	O
epistaxis S-Sign_symptom
was	O
under B-Lab_value
control E-Lab_value
with	O
the	O
use	O
of	O
low B-Dosage
dose E-Dosage
thalidomide S-Medication
.	O

However	O
,	O
she	O
was	O
referred	O
to	O
our	O
clinic S-Nonbiological_location
due	O
to	O
increased S-Detailed_description
epistaxis S-Sign_symptom
severity S-Severity
and	O
frequency S-Frequency
over B-Duration
the I-Duration
prior I-Duration
12 I-Duration
months E-Duration
necessitating	O
more	O
frequent	O
transfusions S-Therapeutic_procedure
.	O

At	O
the	O
time	O
of	O
consultation	O
the	O
patient	O
was	O
concerned	O
about	O
daily S-Frequency
severe S-Severity
left B-Biological_structure
sided E-Biological_structure
epistaxis S-Sign_symptom
despite	O
several B-Duration
months E-Duration
use	O
of	O
topical	O
bevacizumab S-Medication
and	O
oral	O
tranexamic B-Medication
acid E-Medication
.	O

She	O
required	O
intravenous	O
iron S-Medication
and	O
blood B-Therapeutic_procedure
transfusions E-Therapeutic_procedure
every B-Frequency
two I-Frequency
months E-Frequency
.	O

Her	O
baseline	O
hemoglobin S-Diagnostic_procedure
at	O
the	O
time	O
of	O
our	O
consultation	O
was	O
75 B-Lab_value
g I-Lab_value
/ I-Lab_value
L E-Lab_value
(	O
normal	O
=	O
120	O
-	O
160	O
g	O
/	O
L	O
)	O
.	O

Her	O
HHT B-Diagnostic_procedure
epistaxis I-Diagnostic_procedure
severity I-Diagnostic_procedure
score E-Diagnostic_procedure
[	O
17	O
]	O
was	O
severe S-Lab_value
(	O
normalized B-Lab_value
score I-Lab_value
9 I-Lab_value
. I-Lab_value
49 E-Lab_value
)	O
.	O

On	O
examination S-Diagnostic_procedure
,	O
she	O
had	O
multiple S-Detailed_description
telangiectasia S-Sign_symptom
on	O
her	O
fingers S-Biological_structure
,	O
face S-Biological_structure
,	O
lips S-Biological_structure
and	O
palate S-Biological_structure
.	O

Her	O
endoscopic B-Diagnostic_procedure
examination E-Diagnostic_procedure
revealed	O
bilateral S-Detailed_description
telangiectasia S-Sign_symptom
along	O
the	O
nasal B-Biological_structure
septum E-Biological_structure
.	O

There	O
was	O
extensive S-Severity
crusting S-Sign_symptom
along	O
the	O
entire	O
left B-Biological_structure
nasal I-Biological_structure
cavity E-Biological_structure
with	O
which	O
any	O
manipulation S-Diagnostic_procedure
resulted	O
in	O
immediate S-Detailed_description
profuse S-Severity
epistaxis S-Sign_symptom
.	O

Given	O
the	O
severity	O
of	O
the	O
patient	O
`	O
s	O
epistaxis	O
despite	O
medical	O
therapy	O
,	O
she	O
was	O
offered	O
endoscopic B-Detailed_description
left I-Detailed_description
- I-Detailed_description
sided E-Detailed_description
septodermoplasty S-Therapeutic_procedure
.	O

The	O
surgical	O
goals	O
were	O
to	O
improve	O
her	O
quality	O
of	O
life	O
by	O
reducing	O
the	O
number	O
and	O
severity	O
of	O
epistaxis	O
episodes	O
while	O
diminishing	O
the	O
need	O
for	O
blood	O
transfusions	O
.	O

The	O
patient	O
was	O
content	O
with	O
the	O
treatment	O
plan	O
and	O
agreed	O
to	O
undergo	O
surgical	O
intervention	O
.	O

The	O
endoscopic B-Therapeutic_procedure
procedure E-Therapeutic_procedure
was	O
performed	O
under	O
general B-Medication
anesthesia E-Medication
with	O
endotracheal S-Detailed_description
intubation S-Therapeutic_procedure
.	O

The	O
nasal B-Biological_structure
cavity E-Biological_structure
was	O
prepared S-Therapeutic_procedure
by	O
inserting B-Detailed_description
pledgets E-Detailed_description
soaked	O
in	O
topical	O
adrenaline S-Medication
(	O
1:1000 S-Dosage
)	O
placed	O
in	O
both B-Biological_structure
nostrils E-Biological_structure
for	O
decongestion	O
.	O

Using B-Detailed_description
a I-Detailed_description
zero I-Detailed_description
degree I-Detailed_description
endoscope E-Detailed_description
the	O
residual B-Biological_structure
STSG I-Biological_structure
and I-Biological_structure
mucosa I-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
septum E-Biological_structure
was	O
dissected S-Therapeutic_procedure
in B-Detailed_description
a I-Detailed_description
supraperichondrial I-Detailed_description
plane E-Detailed_description
that	O
resulted	O
in	O
the	O
expected	O
significant S-Severity
diffuse S-Detailed_description
hemorrhage S-Sign_symptom
.	O

Immediate S-Detailed_description
hemostasis S-Therapeutic_procedure
was	O
attained	O
using	O
a	O
topical B-Detailed_description
gelatin I-Detailed_description
- I-Detailed_description
thrombin I-Detailed_description
matrix E-Detailed_description
,	O
Floseal S-Detailed_description
(	O
FloSeal	O
Hemostatic	O
Matrix	O
;	O
Baxter	O
Healthcare	O
Corporation	O
,	O
Deerfield	O
,	O
IL	O
,	O
USA	O
)	O
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
mucosal B-Sign_symptom
defect E-Sign_symptom
(	O
Fig	O
.	O
2	O
)	O
measured	O
approximately	O
3 B-Distance
cm E-Distance
in	O
anterior B-Detailed_description
- I-Detailed_description
posterior I-Detailed_description
dimension E-Detailed_description
.	O

A	O
4 B-Area
x I-Area
2 I-Area
cm I-Area
split I-Area
thickness E-Area
skin B-Therapeutic_procedure
graft I-Therapeutic_procedure
was I-Therapeutic_procedure
harvested E-Therapeutic_procedure
from	O
the	O
right B-Biological_structure
thigh E-Biological_structure
,	O
pie B-Detailed_description
- I-Detailed_description
crusted I-Detailed_description
with I-Detailed_description
a I-Detailed_description
15 I-Detailed_description
blade E-Detailed_description
and	O
then	O
placed B-Detailed_description
endoscopically E-Detailed_description
along B-Biological_structure
the I-Biological_structure
length I-Biological_structure
of I-Biological_structure
the I-Biological_structure
septal I-Biological_structure
defect E-Biological_structure
.	O

As	O
seen	O
in	O
Fig	O
.	O
3	O
,	O
the	O
graft	O
was	O
placed	O
with	O
an	O
overlap B-Biological_structure
of I-Biological_structure
the I-Biological_structure
mucosa I-Biological_structure
of I-Biological_structure
the I-Biological_structure
nasal I-Biological_structure
floor I-Biological_structure
and I-Biological_structure
the I-Biological_structure
residual I-Biological_structure
superior I-Biological_structure
septal I-Biological_structure
mucosa E-Biological_structure
.	O

Finally	O
,	O
2 B-Volume
mL E-Volume
of	O
fibrin B-Detailed_description
sealant E-Detailed_description
(	O
TISSEEL	O
fibrin	O
sealant	O
,	O
Baxter	O
Healthcare	O
Corporation	O
,	O
Deerfield	O
,	O
IL	O
,	O
USA	O
)	O
was	O
then	O
applied B-Detailed_description
first I-Detailed_description
to I-Detailed_description
the I-Detailed_description
edges I-Detailed_description
then I-Detailed_description
central I-Detailed_description
portion I-Detailed_description
of I-Detailed_description
the I-Detailed_description
STSG E-Detailed_description
(	O
Fig	O
.	O
4	O
)	O
.	O

Packing S-Therapeutic_procedure
was	O
not	O
used	O
post	O
-	O
operatively	O
and	O
the	O
patient	O
was	O
discharged	O
home S-Nonbiological_location
on	O
the	O
same	O
day	O
of	O
surgery	O
.	O

Clinical	O
follow	O
-	O
up	O
two	O
weeks	O
after	O
surgery	O
(	O
Fig	O
.	O
5	O
)	O
showed	O
that	O
the	O
entire	O
graft B-Sign_symptom
had I-Sign_symptom
taken E-Sign_symptom
and	O
the	O
left B-Detailed_description
- I-Detailed_description
sided E-Detailed_description
epistaxis S-Sign_symptom
had	O
dramatically	O
diminished	O
.	O

The	O
patient	O
was	O
very	O
content	O
with	O
the	O
results	O
of	O
the	O
procedure	O
.	O

At	O
6	O
months	O
follow	O
-	O
up	O
,	O
her	O
baseline	O
hemoglobin S-Diagnostic_procedure
had	O
improved	O
to	O
102 B-Lab_value
g I-Lab_value
/ I-Lab_value
L E-Lab_value
and	O
she	O
was	O
requiring	O
transfusions S-Therapeutic_procedure
every B-Frequency
4 I-Frequency
months E-Frequency
with	O
her	O
hematologist	O
`	O
s	O
intent	O
to	O
stop	O
the	O
transfusions	O
if	O
her	O
hemoglobin	O
remained	O
greater	O
than	O
100	O
g	O
/	O
L	O
.	O

Her	O
epistaxis B-Diagnostic_procedure
severity I-Diagnostic_procedure
score E-Diagnostic_procedure
at	O
6	O
month	O
follow	O
up	O
was	O
mild S-Lab_value
(	O
normalized B-Lab_value
score I-Lab_value
3 I-Lab_value
. I-Lab_value
05 E-Lab_value
)	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
45 B-Age
- I-Age
year I-Age
- I-Age
old E-Age
lady	O
sought	O
dermatology	O
consultation	O
for	O
severely B-Texture
tender E-Texture
erythematous S-Detailed_description
vesicles S-Sign_symptom
and	O
bullae S-Sign_symptom
over	O
back S-Biological_structure
,	O
chest S-Biological_structure
and	O
arms S-Biological_structure
.	O

These	O
were	O
sudden B-Detailed_description
in I-Detailed_description
onset E-Detailed_description
associated	O
with	O
fever S-Sign_symptom
,	O
nausea S-Sign_symptom
and	O
malaise S-Sign_symptom
.	O

Along	O
with	O
this	O
she	O
also	O
complained	O
of	O
pain S-Sign_symptom
in	O
upper B-Biological_structure
abdomen E-Biological_structure
.	O

There	O
was	O
no	O
history	O
of	O
receiving	O
any	O
drugs S-Medication
prior B-Time
to I-Time
the I-Time
onset I-Time
of I-Time
lesions E-Time
.	O

She	O
did	O
not	O
report	O
any	O
significant S-Detailed_description
weight B-Sign_symptom
loss E-Sign_symptom
or	O
loss B-Sign_symptom
of I-Sign_symptom
appetite E-Sign_symptom
.	O

On	O
physical B-Diagnostic_procedure
examination E-Diagnostic_procedure
,	O
her	O
temperature S-Diagnostic_procedure
was	O
38 B-Lab_value
°C E-Lab_value
,	O
pulse B-Diagnostic_procedure
rate E-Diagnostic_procedure
was	O
100 B-Lab_value
/ I-Lab_value
min E-Lab_value
and	O
blood B-Diagnostic_procedure
pressure E-Diagnostic_procedure
was	O
126 B-Lab_value
/ I-Lab_value
72 I-Lab_value
mm I-Lab_value
Hg E-Lab_value
.	O

There	O
were	O
multiple S-Lab_value
coalescing S-Detailed_description
vesicles	O
and	O
bullae	O
over	O
upper B-Biological_structure
back E-Biological_structure
,	O
chest S-Biological_structure
and	O
arms S-Biological_structure
distributed B-Detailed_description
symmetrically E-Detailed_description
showing	O
areas	O
of	O
pustulation S-Sign_symptom
and	O
necrosis S-Sign_symptom
.	O

Surrounding S-Other_entity
them	O
were	O
multiple S-Lab_value
pseudovesicular B-Detailed_description
satellite E-Detailed_description
papule S-Sign_symptom
(	O
figure	O
1A	O
,	O
B	O
)	O
.	O

On	O
per	O
abdominal B-Diagnostic_procedure
examination E-Diagnostic_procedure
mild S-Severity
tenderness S-Sign_symptom
was	O
present	O
in	O
the	O
right B-Biological_structure
hypochondrium E-Biological_structure
.	O

Patient	O
`	O
s	O
initial	O
laboratory B-Diagnostic_procedure
investigations E-Diagnostic_procedure
showed	O
a	O
total B-Diagnostic_procedure
leucocyte I-Diagnostic_procedure
count E-Diagnostic_procedure
of	O
12 B-Lab_value
000 I-Lab_value
cells I-Lab_value
/ I-Lab_value
mm3 E-Lab_value
with	O
75 B-Lab_value
% I-Lab_value
neutrophils E-Lab_value
.	O

The	O
haemoglobin S-Diagnostic_procedure
level	O
was	O
14 B-Lab_value
. I-Lab_value
3 I-Lab_value
gm I-Lab_value
% E-Lab_value
and	O
erythrocyte B-Diagnostic_procedure
sedimentation I-Diagnostic_procedure
rate E-Diagnostic_procedure
was	O
30 B-Lab_value
mm I-Lab_value
/ I-Lab_value
h E-Lab_value
.	O

Liver B-Diagnostic_procedure
function I-Diagnostic_procedure
test E-Diagnostic_procedure
,	O
kidney B-Diagnostic_procedure
function I-Diagnostic_procedure
test E-Diagnostic_procedure
and	O
C B-Diagnostic_procedure
reactive I-Diagnostic_procedure
protein E-Diagnostic_procedure
levels	O
were	O
within	O
normal S-Lab_value
limits	O
.	O

Gram B-Diagnostic_procedure
stain E-Diagnostic_procedure
from	O
purulent B-Diagnostic_procedure
exudates E-Diagnostic_procedure
showed	O
only	O
neutrophils S-Biological_structure
without	O
any	O
organisms S-Sign_symptom
and	O
culture S-Diagnostic_procedure
did	O
not	O
show	O
any	O
growth S-Sign_symptom
after	O
72 B-Duration
h I-Duration
of I-Duration
incubation E-Duration
.	O

A	O
lesional S-Detailed_description
skin S-Biological_structure
biopsy S-Diagnostic_procedure
taken	O
from	O
the	O
satellite S-Detailed_description
papule	O
showed	O
neutrophilic B-Sign_symptom
infiltration E-Sign_symptom
in	O
dermis S-Biological_structure
with	O
papillary B-Sign_symptom
dermal I-Sign_symptom
oedema E-Sign_symptom
and	O
spongiosis S-Sign_symptom
(	O
figure	O
2A	O
,	O
B	O
)	O
.	O

Abdominal S-Biological_structure
ultrasonography S-Diagnostic_procedure
revealed	O
intraluminal S-Detailed_description
gall B-Biological_structure
bladder E-Biological_structure
mass S-Sign_symptom
suggestive	O
of	O
malignancy S-Sign_symptom
.	O

On	O
the	O
basis	O
of	O
these	O
findings	O
a	O
final	O
diagnosis	O
of	O
SS S-Disease_disorder
associated	O
with	O
gall	O
bladder	O
malignancy	O
was	O
made	O
.	O

She	O
was	O
started	O
on	O
oral	O
prednisolone S-Medication
in	O
dose	O
of	O
40 B-Dosage
mg E-Dosage
daily S-Frequency
along	O
with	O
symptomatic S-Detailed_description
treatment S-Medication
.	O

Her	O
cutaneous S-Detailed_description
lesions S-Sign_symptom
responded	O
dramatically	O
and	O
subsided B-Detailed_description
completely E-Detailed_description
after	O
1 B-Duration
week E-Duration
of	O
treatment S-Medication
(	O
figure	O
3A	O
,	O
B	O
)	O
.	O

Dose	O
of	O
prednisolone	O
was	O
tapered	O
and	O
an	O
open S-Detailed_description
cholecystectomy S-Therapeutic_procedure
was	O
performed	O
.	O

Histopathology S-Diagnostic_procedure
of	O
excised B-Biological_structure
tissue E-Biological_structure
confirmed	O
it	O
to	O
be	O
well B-Detailed_description
- I-Detailed_description
differentiated E-Detailed_description
gall B-Biological_structure
bladder E-Biological_structure
adenocarcinoma S-Disease_disorder
forming	O
glands B-Sign_symptom
and E-Sign_symptom
papillae S-Biological_structure
infiltrating B-Sign_symptom
the E-Sign_symptom
muscularis B-Biological_structure
propria E-Biological_structure
superficially S-Detailed_description
.	O

Cystic B-Biological_structure
duct I-Biological_structure
cut I-Biological_structure
margins E-Biological_structure
were	O
free	O
of	O
tumour S-Sign_symptom
(	O
figure	O
2C	O
,	O
D	O
)	O
.	O

Patient	O
`	O
s	O
postoperative B-Duration
period E-Duration
was	O
uneventful S-Sign_symptom
and	O
she	O
was	O
discharged	O
on	O
tapering B-Dosage
doses E-Dosage
of	O
prednisolone	O
with	O
advice	O
to	O
follow	O
-	O
up	O
periodically	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
44 B-Age
- I-Age
year I-Age
- I-Age
old E-Age
man	O
had	O
been	O
diagnosed	O
with	O
LCNEC S-Disease_disorder
of	O
the	O
thymus S-Biological_structure
with	O
bone S-Biological_structure
metastasis S-Sign_symptom
at	O
a	O
different B-Nonbiological_location
hospital E-Nonbiological_location
3	O
years	O
previously	O
.	O

The	O
serum	O
levels	O
of	O
ACTH S-Diagnostic_procedure
and	O
cortisol S-Diagnostic_procedure
were	O
elevated S-Lab_value
,	O
but	O
brain S-Biological_structure
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging E-Diagnostic_procedure
revealed	O
that	O
his	O
pituitary B-Detailed_description
gland E-Detailed_description
was	O
normal S-Lab_value
.	O

However	O
,	O
immunohistochemical B-Diagnostic_procedure
staining E-Diagnostic_procedure
of	O
the	O
thymic B-Biological_structure
tumor I-Biological_structure
tissue E-Biological_structure
revealed	O
partial S-Lab_value
anti B-Diagnostic_procedure
- I-Diagnostic_procedure
ACTH I-Diagnostic_procedure
antibody E-Diagnostic_procedure
positivity S-Lab_value
.	O

The	O
tumor	O
was	O
therefore	O
determined	O
to	O
be	O
ectopically B-Detailed_description
producing I-Detailed_description
ACTH E-Detailed_description
.	O

The	O
patient	O
underwent	O
chemotherapy S-Medication
with	O
cisplatin S-Medication
and	O
irinotecan S-Medication
,	O
but	O
the	O
continuation	O
of	O
chemotherapy	O
was	O
problematic B-Detailed_description
due I-Detailed_description
to I-Detailed_description
a I-Detailed_description
lack I-Detailed_description
of I-Detailed_description
tolerance E-Detailed_description
.	O

Treatment	O
for	O
hypertension S-Sign_symptom
and	O
diabetes S-Disease_disorder
caused	O
by	O
the	O
ectopic B-Disease_disorder
ACTH I-Disease_disorder
syndrome E-Disease_disorder
was	O
initiated	O
,	O
as	O
was	O
treatment	O
with	O
zoledronic B-Medication
acid E-Medication
for	O
bone S-Biological_structure
metastasis S-Sign_symptom
.	O

The	O
patient	O
was	O
referred	O
to	O
the	O
Endocrine B-Nonbiological_location
Center I-Nonbiological_location
at I-Nonbiological_location
our I-Nonbiological_location
hospital E-Nonbiological_location
after	O
3	O
months	O
due	O
to	O
a	O
sensation B-Sign_symptom
of I-Sign_symptom
weakness E-Sign_symptom
and	O
the	O
worsening	O
of	O
his	O
hyperglycemia S-Sign_symptom
.	O

A	O
physical B-Diagnostic_procedure
examination E-Diagnostic_procedure
revealed	O
hypertension S-Sign_symptom
,	O
a	O
subcutaneous S-Detailed_description
mass S-Sign_symptom
that	O
was	O
palpable S-Detailed_description
in	O
the	O
anterior B-Biological_structure
chest E-Biological_structure
,	O
and	O
redness S-Sign_symptom
and	O
swelling S-Sign_symptom
of	O
the	O
left B-Biological_structure
lower I-Biological_structure
leg E-Biological_structure
without	O
fever S-Sign_symptom
,	O
respiratory B-Sign_symptom
symptoms E-Sign_symptom
,	O
hypoxemia S-Sign_symptom
,	O
or	O
abnormal B-Sign_symptom
chest I-Sign_symptom
sounds E-Sign_symptom
.	O

The	O
oxygen B-Diagnostic_procedure
saturation E-Diagnostic_procedure
by	O
pulse B-Detailed_description
oximeter E-Detailed_description
in	O
room B-Detailed_description
air E-Detailed_description
and	O
was	O
97 B-Lab_value
% E-Lab_value
and	O
his	O
respiratory B-Diagnostic_procedure
rate E-Diagnostic_procedure
was	O
13 B-Lab_value
breaths I-Lab_value
per I-Lab_value
minute E-Lab_value
.	O

Among	O
the	O
laboratory B-Diagnostic_procedure
findings E-Diagnostic_procedure
,	O
the	O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell E-Diagnostic_procedure
and	O
neutrophil S-Diagnostic_procedure
counts	O
,	O
and	O
blood B-Diagnostic_procedure
sugar E-Diagnostic_procedure
,	O
triglyceride S-Diagnostic_procedure
,	O
and	O
low B-Diagnostic_procedure
- I-Diagnostic_procedure
density I-Diagnostic_procedure
lipoprotein I-Diagnostic_procedure
cholesterol E-Diagnostic_procedure
levels	O
were	O
found	O
to	O
be	O
elevated S-Lab_value
,	O
and	O
the	O
patient	O
`	O
s	O
potassium S-Diagnostic_procedure
level	O
was	O
decreased S-Lab_value
to	O
2 B-Lab_value
. I-Lab_value
8 I-Lab_value
mEq I-Lab_value
/ I-Lab_value
L E-Lab_value
.	O

The	O
patient	O
`	O
s	O
lactate B-Diagnostic_procedure
dehydrogenase E-Diagnostic_procedure
(	O
468 B-Lab_value
IU I-Lab_value
/ I-Lab_value
L E-Lab_value
)	O
,	O
beta B-Diagnostic_procedure
- I-Diagnostic_procedure
D I-Diagnostic_procedure
glucan E-Diagnostic_procedure
(	O
370 B-Lab_value
. I-Lab_value
8 I-Lab_value
pg I-Lab_value
/ I-Lab_value
mL E-Lab_value
)	O
,	O
ACTH S-Diagnostic_procedure
(	O
354 B-Lab_value
. I-Lab_value
1 I-Lab_value
pg I-Lab_value
/ I-Lab_value
mL E-Lab_value
)	O
,	O
and	O
cortisol S-Diagnostic_procedure
(	O
49 B-Lab_value
. I-Lab_value
1 I-Lab_value
μg I-Lab_value
/ I-Lab_value
dL E-Lab_value
)	O
levels	O
were	O
also	O
elevated S-Lab_value
.	O

The	O
patient	O
`	O
s	O
serum S-Diagnostic_procedure
was	O
negative S-Lab_value
for	O
aspergillus S-Diagnostic_procedure
,	O
candida S-Diagnostic_procedure
,	O
and	O
cryptococcus B-Diagnostic_procedure
antigens E-Diagnostic_procedure
;	O
a	O
cytomegalovirus B-Diagnostic_procedure
pp65 I-Diagnostic_procedure
antigenemia I-Diagnostic_procedure
test E-Diagnostic_procedure
also	O
yielded	O
a	O
negative S-Lab_value
result	O
.	O

These	O
data	O
suggested	O
that	O
the	O
increased	O
production	O
of	O
ACTH	O
by	O
the	O
tumor	O
,	O
along	O
with	O
the	O
progression	O
of	O
the	O
disease	O
,	O
had	O
promoted	O
the	O
elevation	O
of	O
the	O
patient	O
`	O
s	O
serum	O
levels	O
of	O
ACTH	O
and	O
cortisol	O
.	O

Computed B-Diagnostic_procedure
tomography E-Diagnostic_procedure
(	O
CT S-Diagnostic_procedure
)	O
revealed	O
the	O
progression B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
disease E-Sign_symptom
in	O
the	O
both	O
thymic S-Biological_structure
and	O
metastatic S-Detailed_description
bone S-Biological_structure
lesions S-Sign_symptom
,	O
along	O
with	O
the	O
multiple S-Detailed_description
ground B-Texture
- I-Texture
glass E-Texture
opacities S-Sign_symptom
in	O
both B-Biological_structure
lungs E-Biological_structure
(	O
Fig	O
.	O
1	O
,	O
2	O
)	O
.	O

The	O
patient	O
underwent	O
bronchoalveolar B-Diagnostic_procedure
lavage E-Diagnostic_procedure
(	O
BAL S-Diagnostic_procedure
)	O
in	O
the	O
right B-Biological_structure
B5 I-Biological_structure
segment E-Biological_structure
with	O
150 B-Detailed_description
mL I-Detailed_description
saline E-Detailed_description
,	O
and	O
62 B-Lab_value
. I-Lab_value
7 I-Lab_value
% I-Lab_value
of I-Lab_value
the I-Lab_value
BAL I-Lab_value
fluid I-Lab_value
was I-Lab_value
recovered E-Lab_value
.	O

The	O
cell B-Diagnostic_procedure
count E-Diagnostic_procedure
in	O
the	O
BAL B-Detailed_description
fluid E-Detailed_description
was	O
0 B-Lab_value
. I-Lab_value
61 I-Lab_value
× I-Lab_value
105 I-Lab_value
per I-Lab_value
mL E-Lab_value
,	O
and	O
the	O
cell B-Diagnostic_procedure
differentiation E-Diagnostic_procedure
in	O
the	O
BAL B-Detailed_description
fluid E-Detailed_description
was	O
17 B-Lab_value
. I-Lab_value
0 I-Lab_value
% I-Lab_value
macrophages E-Lab_value
,	O
81 B-Lab_value
. I-Lab_value
0 I-Lab_value
% I-Lab_value
lymphocytes E-Lab_value
,	O
and	O
2 B-Lab_value
. I-Lab_value
0 I-Lab_value
% I-Lab_value
neutrophils E-Lab_value
,	O
with	O
a	O
CD B-Lab_value
4 I-Lab_value
/ I-Lab_value
8 I-Lab_value
ratio I-Lab_value
of I-Lab_value
0 I-Lab_value
. I-Lab_value
57 E-Lab_value
.	O

Gram S-Diagnostic_procedure
,	O
Ziehl B-Diagnostic_procedure
- I-Diagnostic_procedure
Neelsen E-Diagnostic_procedure
,	O
and	O
Grocott B-Diagnostic_procedure
staining E-Diagnostic_procedure
were	O
all	O
negative S-Lab_value
.	O

A	O
polymerase B-Diagnostic_procedure
chain I-Diagnostic_procedure
reaction E-Diagnostic_procedure
revealed	O
that	O
the	O
patient	O
`	O
s	O
BAL B-Detailed_description
fluid E-Detailed_description
was	O
positive S-Lab_value
for	O
Pneumocystis B-Diagnostic_procedure
jirovecii E-Diagnostic_procedure
.	O

PCP S-Disease_disorder
was	O
diagnosed	O
based	O
on	O
the	O
above	O
results	O
.	O

The	O
patient	O
was	O
treated	O
with	O
sulfamethoxazole B-Medication
/ I-Medication
trimethoprim E-Medication
(	O
12 B-Dosage
g I-Dosage
/ I-Dosage
day E-Dosage
)	O
for	O
3 B-Duration
weeks E-Duration
.	O

Anti B-Therapeutic_procedure
- I-Therapeutic_procedure
cortisol I-Therapeutic_procedure
therapy E-Therapeutic_procedure
with	O
metyrapone S-Medication
was	O
also	O
initiated	O
at	O
the	O
same	O
time	O
with	O
a	O
small B-Dosage
dose E-Dosage
to	O
slowly	O
correct	O
the	O
hypercortisolemia S-Disease_disorder
.	O

Intensive	O
insulin S-Medication
therapy	O
,	O
potassium S-Medication
supplementation	O
were	O
initiated	O
,	O
while	O
cefazolin S-Medication
was	O
administered	O
to	O
treat	O
cellulitis S-Disease_disorder
of	O
the	O
left B-Biological_structure
lower I-Biological_structure
leg E-Biological_structure
.	O

The	O
patient	O
`	O
s	O
PCP S-Disease_disorder
fully	O
improved	O
without	O
the	O
exacerbation S-Sign_symptom
of	O
his	O
respiratory B-Diagnostic_procedure
status E-Diagnostic_procedure
.	O

Thereafter	O
,	O
we	O
continued	O
to	O
administer	O
sulfamethoxazole B-Medication
/ I-Medication
trimethoprim E-Medication
at	O
a	O
prophylactic B-Dosage
dose E-Dosage
.	O

The	O
metyrapone S-Medication
dosage	O
was	O
gradually	O
increased	O
from	O
250 B-Dosage
mg I-Dosage
/ I-Dosage
day E-Dosage
,	O
and	O
the	O
blood B-Diagnostic_procedure
cortisol E-Diagnostic_procedure
value	O
was	O
observed	O
to	O
decline B-Lab_value
slowly E-Lab_value
(	O
Fig	O
.	O
3	O
)	O
.	O

In	O
order	O
to	O
prevent	O
hypocortisolemia	O
,	O
the	O
patient	O
was	O
temporarily S-Detailed_description
treated	O
with	O
hydrocortisone S-Medication
.	O

After	O
an	O
improvement	O
of	O
his	O
left B-Biological_structure
lower I-Biological_structure
leg E-Biological_structure
cellulitis S-Disease_disorder
,	O
PCP S-Disease_disorder
,	O
and	O
hyperglycemia S-Disease_disorder
,	O
the	O
patient	O
underwent	O
laminectomy S-Therapeutic_procedure
and	O
radiation B-Therapeutic_procedure
therapy E-Therapeutic_procedure
for	O
spinal B-Disease_disorder
cord I-Disease_disorder
compression E-Disease_disorder
,	O
which	O
had	O
been	O
caused	O
by	O
a	O
metastatic S-Detailed_description
spinal S-Biological_structure
tumor S-Sign_symptom
.	O

Octreotide S-Medication
therapy	O
was	O
initiated	O
,	O
and	O
he	O
was	O
discharged	O
on	O
the	O
68th	O
day	O
of	O
hospitalization	O
.	O

-DOCSTART- -X- -X- -X- O

Our	O
patient	O
was	O
a	O
7 B-Age
- I-Age
year I-Age
- I-Age
old E-Age
Italian	O
boy	O
born	O
after	O
an	O
uneventful	O
gestation	O
of	O
normal	O
duration	O
.	O

At	O
the	O
age	O
of	O
16	O
months	O
,	O
he	O
presented	O
with	O
a	O
clinically B-Detailed_description
evident E-Detailed_description
enlarged S-Sign_symptom
abdomen S-Biological_structure
and	O
was	O
referred	O
for	O
oncological B-Nonbiological_location
examination E-Nonbiological_location
.	O

Initial	O
tests	O
revealed	O
anemia S-Sign_symptom
,	O
thrombocytopenia S-Sign_symptom
,	O
and	O
splenomegaly S-Sign_symptom
.	O

A	O
bone B-Biological_structure
marrow E-Biological_structure
biopsy S-Diagnostic_procedure
revealed	O
the	O
presence	O
of	O
foam B-Sign_symptom
cells E-Sign_symptom
,	O
which	O
led	O
to	O
suspicion	O
of	O
lysosomal B-Disease_disorder
storage I-Disease_disorder
disease E-Disease_disorder
.	O

Biochemical B-Diagnostic_procedure
testing E-Diagnostic_procedure
revealed	O
elevated S-Lab_value
level	O
of	O
acid B-Diagnostic_procedure
phosphatase E-Diagnostic_procedure
(	O
47 B-Lab_value
. I-Lab_value
8 I-Lab_value
IU I-Lab_value
/ I-Lab_value
L E-Lab_value
[	O
normal	O
range	O
5	O
-	O
7	O
IU	O
/	O
L	O
]	O
)	O
and	O
chitotriosidase B-Diagnostic_procedure
activity E-Diagnostic_procedure
(	O
508 B-Lab_value
nmol I-Lab_value
/ I-Lab_value
mg I-Lab_value
protein E-Lab_value
[	O
normal	O
range	O
5	O
.	O
9	O
-	O
41	O
.	O
0	O
nmol	O
/	O
mg	O
protein	O
]	O
)	O
,	O
as	O
well	O
as	O
reduced S-Lab_value
beta B-Diagnostic_procedure
- I-Diagnostic_procedure
glucosidase I-Diagnostic_procedure
activity E-Diagnostic_procedure
(	O
2 B-Lab_value
nmol I-Lab_value
/ I-Lab_value
mg I-Lab_value
/ I-Lab_value
protein E-Lab_value
[	O
normal	O
range	O
4	O
.	O
5	O
-	O
18	O
.	O
0	O
nmol	O
/	O
mg	O
/	O
protein	O
]	O
)	O
.	O

Molecular B-Diagnostic_procedure
analysis E-Diagnostic_procedure
showed	O
homozygous B-Detailed_description
L444P E-Detailed_description
mutations B-Sign_symptom
in I-Sign_symptom
the I-Sign_symptom
GBA I-Sign_symptom
gene E-Sign_symptom
(	O
OMIM	O
reference	O
606463	O
)	O
,	O
confirming	O
the	O
diagnosis	O
of	O
chronic	O
NGD S-Disease_disorder
.	O

The	O
patient	O
began	O
ERT S-Therapeutic_procedure
at	O
a	O
dosage	O
of	O
60 B-Dosage
U I-Dosage
/ I-Dosage
kg I-Dosage
every I-Dosage
2 I-Dosage
weeks E-Dosage
at	O
the	O
age	O
of	O
18	O
months	O
.	O

Thereafter	O
,	O
when	O
the	O
patient	O
reached	O
the	O
age	O
of	O
30	O
months	O
,	O
we	O
decided	O
to	O
combine	O
ERT S-Therapeutic_procedure
with	O
SRT S-Therapeutic_procedure
with	O
miglustat S-Medication
.	O

This	O
clinical	O
decision	O
was	O
approved	O
by	O
our	O
institution	O
`	O
s	O
ethics	O
committee	O
,	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patient	O
`	O
s	O
parents	O
before	O
commencing	O
combination	O
therapy	O
.	O

The	O
dose	O
of	O
miglustat S-Medication
was	O
adjusted B-Detailed_description
according I-Detailed_description
to I-Detailed_description
the I-Detailed_description
patient I-Detailed_description
` I-Detailed_description
s I-Detailed_description
body I-Detailed_description
surface I-Detailed_description
area E-Detailed_description
and	O
was	O
uptitrated	O
during	O
the	O
first	O
4	O
weeks	O
with	O
the	O
following	O
scheme	O
:	O
one	O
-	O
third	O
of	O
target	O
dose	O
during	O
weeks	O
1	O
and	O
2	O
,	O
two	O
-	O
thirds	O
of	O
target	O
dose	O
during	O
weeks	O
3	O
and	O
4	O
,	O
and	O
target	O
dose	O
(	O
100 B-Dosage
mg I-Dosage
three I-Dosage
times I-Dosage
daily E-Dosage
)	O
after	O
1	O
month	O
.	O

From	O
2	O
weeks	O
before	O
starting	O
miglustat S-Medication
therapy	O
,	O
the	O
patient	O
also	O
followed	O
specific	O
dietary B-Therapeutic_procedure
modifications E-Therapeutic_procedure
,	O
avoiding B-Detailed_description
high I-Detailed_description
intake I-Detailed_description
of I-Detailed_description
carbohydrate I-Detailed_description
- I-Detailed_description
containing I-Detailed_description
food I-Detailed_description
in I-Detailed_description
single I-Detailed_description
meals E-Detailed_description
,	O
especially	O
foods B-Detailed_description
high I-Detailed_description
in I-Detailed_description
disaccharides I-Detailed_description
, I-Detailed_description
such I-Detailed_description
as I-Detailed_description
sucrose I-Detailed_description
and I-Detailed_description
maltose E-Detailed_description
,	O
to	O
ensure	O
acceptable	O
gastrointestinal	O
tolerability	O
.	O

He	O
experienced	O
mild S-Severity
episodes	O
of	O
diarrhea S-Sign_symptom
after	O
commencing	O
miglustat S-Medication
therapy	O
,	O
which	O
decreased B-Lab_value
in I-Lab_value
frequency I-Lab_value
/ I-Lab_value
severity I-Lab_value
over I-Lab_value
time E-Lab_value
.	O

From	O
the	O
start	O
of	O
ERT	O
/	O
miglustat	O
combination	O
treatment	O
,	O
we	O
observed	O
a	O
reduction	O
in	O
splenomegaly S-Sign_symptom
and	O
a	O
gradual	O
normalization S-Lab_value
of	O
hematological B-Diagnostic_procedure
values E-Diagnostic_procedure
and	O
plasma B-Diagnostic_procedure
angiotensin I-Diagnostic_procedure
- I-Diagnostic_procedure
converting I-Diagnostic_procedure
enzyme I-Diagnostic_procedure
activity E-Diagnostic_procedure
(	O
Table	O
1	O
)	O
.	O

Plasma B-Diagnostic_procedure
chitotriosidase E-Diagnostic_procedure
was	O
evaluated	O
at	O
the	O
time	O
of	O
diagnosis	O
and	O
then	O
approximately	O
every B-Frequency
6 I-Frequency
months E-Frequency
during	O
follow	O
-	O
up	O
.	O

Values	O
showed	O
an	O
initial B-Lab_value
reduction E-Lab_value
after B-Detailed_description
the I-Detailed_description
start I-Detailed_description
of I-Detailed_description
ERT E-Detailed_description
,	O
with	O
a	O
further	O
,	O
substantial	O
,	O
and	O
sustained B-Lab_value
decrease E-Lab_value
after B-Detailed_description
commencement I-Detailed_description
of I-Detailed_description
miglustat E-Detailed_description
treatment	O
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
patient	O
has	O
been	O
followed	O
according B-Detailed_description
to I-Detailed_description
recommended I-Detailed_description
guidelines I-Detailed_description
for I-Detailed_description
GD E-Detailed_description
,	O
which	O
specify	O
a	O
complete	O
neurological B-Diagnostic_procedure
examination E-Diagnostic_procedure
,	O
clinical	O
evaluation B-Diagnostic_procedure
of I-Diagnostic_procedure
ocular I-Diagnostic_procedure
movements E-Diagnostic_procedure
,	O
and	O
psychological B-Diagnostic_procedure
evaluations E-Diagnostic_procedure
every B-Frequency
6 I-Frequency
- I-Frequency
12 I-Frequency
months E-Frequency
[	O
10	O
]	O
.	O

After	O
5 B-Duration
years E-Duration
of	O
combination B-Therapeutic_procedure
therapy E-Therapeutic_procedure
and	O
follow	O
-	O
up	O
,	O
the	O
patient	O
did	O
not	O
show	O
any	O
signs	O
of	O
neurological B-Sign_symptom
impairment E-Sign_symptom
.	O

As	O
of	O
February	O
2016	O
,	O
he	O
had	O
not	O
displayed	O
any	O
epileptic B-Sign_symptom
crises E-Sign_symptom
and	O
had	O
demonstrated	O
clinical B-Sign_symptom
performance E-Sign_symptom
and	O
cooperation S-Activity
.	O

He	O
showed	O
good S-Lab_value
muscular B-Diagnostic_procedure
tone I-Diagnostic_procedure
and I-Diagnostic_procedure
trophism E-Diagnostic_procedure
,	O
normal S-Lab_value
reflexes S-Diagnostic_procedure
with	O
a	O
slight S-Severity
hyperreflexia S-Sign_symptom
in	O
his	O
legs S-Biological_structure
,	O
and	O
a	O
negative S-Lab_value
Romberg B-Diagnostic_procedure
sign E-Diagnostic_procedure
.	O

His	O
toe B-Diagnostic_procedure
and I-Diagnostic_procedure
heel I-Diagnostic_procedure
deambulation E-Diagnostic_procedure
was	O
normal S-Lab_value
.	O

In	O
particular	O
,	O
ocular B-Diagnostic_procedure
evaluations E-Diagnostic_procedure
revealed	O
no	O
evidence	O
of	O
saccadic B-Sign_symptom
movement I-Sign_symptom
velocity I-Sign_symptom
reduction E-Sign_symptom
and	O
normal S-Lab_value
visual B-Diagnostic_procedure
evoked I-Diagnostic_procedure
potentials E-Diagnostic_procedure
.	O

The	O
patient	O
`	O
s	O
auditory B-Diagnostic_procedure
brain I-Diagnostic_procedure
responses E-Diagnostic_procedure
were	O
also	O
normal S-Lab_value
.	O

In	O
addition	O
,	O
he	O
has	O
not	O
demonstrated	O
any	O
cognitive B-Sign_symptom
impairment E-Sign_symptom
,	O
and	O
he	O
has	O
regularly S-Detailed_description
attended B-Activity
school E-Activity
with	O
good B-Detailed_description
performance E-Detailed_description
since	O
the	O
age	O
of	O
5	O
years	O
.	O

-DOCSTART- -X- -X- -X- O

An	O
84 B-Age
- I-Age
year I-Age
- I-Age
old E-Age
woman	O
presented	O
to	O
a	O
local B-Nonbiological_location
clinic E-Nonbiological_location
with	O
dyspnea S-Sign_symptom
on B-Detailed_description
exertion E-Detailed_description
and	O
left B-Biological_structure
back E-Biological_structure
pain S-Sign_symptom
persisting B-Duration
for I-Duration
a I-Duration
month E-Duration
.	O

She	O
was	O
admitted	O
to	O
our	O
hospital S-Nonbiological_location
because	O
of	O
left S-Detailed_description
pleural B-Sign_symptom
effusion E-Sign_symptom
on	O
a	O
chest S-Biological_structure
X B-Diagnostic_procedure
- I-Diagnostic_procedure
ray E-Diagnostic_procedure
.	O

She	O
suffered	O
hypertension	O
and	O
dyslipidemia	O
but	O
had	O
no	O
history	O
of	O
pleural	O
tuberculosis	O
or	O
chronic	O
pyothorax	O
,	O
nor	O
a	O
smoking	O
history	O
or	O
dust	O
exposure	O
.	O

On	O
examination S-Diagnostic_procedure
,	O
her	O
vital B-Diagnostic_procedure
signs E-Diagnostic_procedure
and	O
oxygen B-Diagnostic_procedure
saturation E-Diagnostic_procedure
were	O
normal S-Lab_value
(	O
SpO2 S-Diagnostic_procedure
:	O
96 B-Lab_value
% E-Lab_value
ambient B-Detailed_description
air E-Detailed_description
)	O
.	O

A	O
chest B-Diagnostic_procedure
examination E-Diagnostic_procedure
revealed	O
a	O
mass S-Sign_symptom
on	O
the	O
left B-Biological_structure
side I-Biological_structure
of I-Biological_structure
her I-Biological_structure
back E-Biological_structure
with	O
pain S-Sign_symptom
and	O
decreased B-Sign_symptom
breathing I-Sign_symptom
sounds E-Sign_symptom
in	O
the	O
left B-Biological_structure
lower I-Biological_structure
- I-Biological_structure
lung I-Biological_structure
field E-Biological_structure
.	O

The B-Detailed_description
rest E-Detailed_description
of	O
the	O
examination B-Diagnostic_procedure
findings E-Diagnostic_procedure
were	O
normal S-Lab_value
.	O

Laboratory B-Diagnostic_procedure
tests E-Diagnostic_procedure
revealed	O
elevated B-Lab_value
levels E-Lab_value
of	O
C B-Diagnostic_procedure
reactive I-Diagnostic_procedure
protein E-Diagnostic_procedure
,	O
lactate B-Diagnostic_procedure
dehydrogenase E-Diagnostic_procedure
(	O
LDH S-Diagnostic_procedure
)	O
,	O
and	O
soluble B-Diagnostic_procedure
interleukin I-Diagnostic_procedure
- I-Diagnostic_procedure
2 I-Diagnostic_procedure
receptor E-Diagnostic_procedure
(	O
sIL B-Diagnostic_procedure
- I-Diagnostic_procedure
2R E-Diagnostic_procedure
)	O
(	O
Table	O
1	O
)	O
.	O

A	O
chest S-Biological_structure
X B-Diagnostic_procedure
- I-Diagnostic_procedure
ray E-Diagnostic_procedure
(	O
Fig	O
.	O
1	O
)	O
showed	O
left S-Detailed_description
pleural B-Sign_symptom
effusion E-Sign_symptom
with	O
mediastinal B-Detailed_description
shift E-Detailed_description
.	O

On	O
the	O
first	O
hospital	O
day	O
,	O
an	O
intercostal S-Biological_structure
drainage B-Therapeutic_procedure
tube E-Therapeutic_procedure
was	O
inserted	O
,	O
and	O
after	O
drainage	O
,	O
chest S-Biological_structure
computed B-Diagnostic_procedure
tomography E-Diagnostic_procedure
(	O
CT S-Diagnostic_procedure
)	O
(	O
Fig	O
.	O
2	O
)	O
revealed	O
an	O
irregular S-Detailed_description
pleural S-Biological_structure
mass S-Sign_symptom
invading	O
her	O
left B-Biological_structure
chest I-Biological_structure
wall E-Biological_structure
with	O
rib S-Biological_structure
destruction S-Sign_symptom
and	O
pleural B-Sign_symptom
effusion E-Sign_symptom
.	O

The	O
mass S-Sign_symptom
was	O
adjacent B-Biological_structure
to I-Biological_structure
the I-Biological_structure
posterior I-Biological_structure
mediastinum E-Biological_structure
,	O
but	O
the	O
lateral B-Detailed_description
side E-Detailed_description
of	O
the	O
mass S-Sign_symptom
was	O
thick S-Detailed_description
and	O
invading	O
the	O
chest B-Biological_structure
wall E-Biological_structure
,	O
so	O
we	O
diagnosed	O
this	O
mass S-Sign_symptom
as	O
a	O
chest B-Disease_disorder
wall I-Disease_disorder
tumor E-Disease_disorder
.	O

The	O
pleural B-Biological_structure
fluid E-Biological_structure
was	O
serous S-Sign_symptom
and	O
not	O
purulent S-Sign_symptom
.	O

A	O
fluid B-Diagnostic_procedure
analysis E-Diagnostic_procedure
showed	O
it	O
to	O
be	O
exudative S-Lab_value
,	O
and	O
81 B-Lab_value
% I-Lab_value
of I-Lab_value
the I-Lab_value
white I-Lab_value
blood I-Lab_value
cells I-Lab_value
were I-Lab_value
lymphocytes E-Lab_value
.	O

The	O
fluid B-Diagnostic_procedure
culture E-Diagnostic_procedure
was	O
negative S-Lab_value
,	O
and	O
cytology S-Diagnostic_procedure
did	O
not	O
show	O
any	O
evidence	O
of	O
malignancy S-Sign_symptom
(	O
Table	O
1	O
)	O
.	O

CT B-Detailed_description
- I-Detailed_description
guided I-Detailed_description
needle E-Detailed_description
biopsy S-Diagnostic_procedure
was	O
performed	O
.	O

The	O
histopathology S-Diagnostic_procedure
results	O
supported	O
a	O
diagnosis	O
of	O
diffuse B-Disease_disorder
large I-Disease_disorder
B I-Disease_disorder
- I-Disease_disorder
cell I-Disease_disorder
lymphoma E-Disease_disorder
(	O
DLBCL S-Disease_disorder
)	O
that	O
was	O
positive S-Lab_value
for	O
CD10 S-Diagnostic_procedure
and	O
CD20 S-Diagnostic_procedure
but	O
negative S-Lab_value
for	O
CD3 S-Diagnostic_procedure
and	O
CD5 S-Diagnostic_procedure
(	O
Fig	O
.	O
3	O
)	O
.	O

18 B-Diagnostic_procedure
- I-Diagnostic_procedure
fluorodeoxyglucose I-Diagnostic_procedure
positron I-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography I-Diagnostic_procedure
/ I-Diagnostic_procedure
computed I-Diagnostic_procedure
tomography E-Diagnostic_procedure
(	O
FDG B-Diagnostic_procedure
- I-Diagnostic_procedure
PET I-Diagnostic_procedure
/ I-Diagnostic_procedure
CT E-Diagnostic_procedure
)	O
revealed	O
high B-Sign_symptom
FDG I-Sign_symptom
uptake E-Sign_symptom
in	O
the	O
left B-Biological_structure
chest I-Biological_structure
wall E-Biological_structure
mass S-Sign_symptom
without	O
any	O
other	O
uptake	O
(	O
Fig	O
.	O
4A	O
and	O
B	O
)	O
,	O
so	O
we	O
diagnosed	O
her	O
with	O
primary B-Disease_disorder
malignant I-Disease_disorder
lymphoma E-Disease_disorder
originating B-Biological_structure
from I-Biological_structure
the I-Biological_structure
chest I-Biological_structure
wall E-Biological_structure
.	O

We	O
reconfirmed	O
her	O
medical	O
history	O
,	O
and	O
she	O
never	O
had	O
either	O
tuberculous	O
pleurisy	O
or	O
pyothorax	O
.	O

Her	O
performance B-Diagnostic_procedure
status E-Diagnostic_procedure
(	O
PS S-Diagnostic_procedure
)	O
was	O
3 S-Lab_value
because	O
of	O
her	O
back S-Biological_structure
pain S-Sign_symptom
and	O
fatigue S-Sign_symptom
.	O

Owing	O
to	O
her	O
bad	O
PS	O
and	O
age	O
,	O
it	O
was	O
difficult	O
to	O
perform	O
an	O
operation	O
or	O
administer	O
combination	O
chemotherapy	O
with	O
Rituximab S-Medication
,	O
so	O
low B-Detailed_description
- I-Detailed_description
dose E-Detailed_description
oral	O
etoposide S-Medication
(	O
50 B-Dosage
mg I-Dosage
/ I-Dosage
day I-Dosage
d1 I-Dosage
- I-Dosage
14 I-Dosage
, I-Dosage
q28 E-Dosage
)	O
was	O
administered	O
.	O

Her	O
pleural B-Sign_symptom
effusion E-Sign_symptom
disappeared	O
within	O
two	O
weeks	O
,	O
her	O
back S-Biological_structure
pain S-Sign_symptom
disappeared	O
,	O
and	O
her	O
PS S-Diagnostic_procedure
improved	O
to	O
1 S-Lab_value
within	O
a	O
month	O
.	O

Chest B-Diagnostic_procedure
CT E-Diagnostic_procedure
performed	O
four	O
months	O
later	O
showed	O
complete B-Lab_value
response E-Lab_value
(	O
Fig	O
.	O
4C	O
and	O
D	O
)	O
.	O

She	O
continued	O
oral	O
chemotherapy S-Medication
and	O
maintained	O
a	O
good S-Lab_value
PS S-Diagnostic_procedure
for	O
one	O
year	O
after	O
the	O
diagnosis	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
73 B-Age
- I-Age
year I-Age
- I-Age
old E-Age
woman	O
was	O
initially	O
referred	O
19	O
months	O
prior	O
to	O
the	O
current	O
presentation	O
,	O
at	O
which	O
time	O
fluorescein S-Detailed_description
and	O
indocyanine B-Detailed_description
green E-Detailed_description
angiography S-Diagnostic_procedure
showed	O
a	O
medium B-Detailed_description
- I-Detailed_description
sized I-Detailed_description
subfoveal I-Detailed_description
classic E-Detailed_description
CNV S-Disease_disorder
in	O
the	O
left B-Biological_structure
eye E-Biological_structure
,	O
which	O
had	O
not B-Detailed_description
been I-Detailed_description
previously I-Detailed_description
treated E-Detailed_description
.	O

She	O
did	O
not	O
return	O
for	O
treatment S-Therapeutic_procedure
until	O
the	O
current	O
presentation	O
,	O
when	O
she	O
noted	O
decreased B-Sign_symptom
vision E-Sign_symptom
in	O
the	O
left B-Biological_structure
eye E-Biological_structure
.	O

The	O
best B-Diagnostic_procedure
- I-Diagnostic_procedure
corrected I-Diagnostic_procedure
visual I-Diagnostic_procedure
acuity E-Diagnostic_procedure
(	O
BCVA S-Diagnostic_procedure
)	O
was	O
20 B-Lab_value
/ I-Lab_value
100 E-Lab_value
.	O

Slit B-Diagnostic_procedure
lamp I-Diagnostic_procedure
examination E-Diagnostic_procedure
showed	O
a	O
small S-Detailed_description
yellowish S-Color
patch S-Sign_symptom
in	O
the	O
perifoveal B-Biological_structure
region E-Biological_structure
and	O
retinal B-Sign_symptom
edema E-Sign_symptom
.	O

Structural S-Detailed_description
OCT S-Diagnostic_procedure
revealed	O
the	O
retinal B-Sign_symptom
elevation E-Sign_symptom
,	O
subretinal B-Sign_symptom
fluid E-Sign_symptom
and	O
a	O
hyper B-Biological_structure
- I-Biological_structure
reflective E-Biological_structure
elongated B-Sign_symptom
area E-Sign_symptom
above B-Biological_structure
RPE E-Biological_structure
indicating	O
type B-Lab_value
II E-Lab_value
CNV S-Disease_disorder
.	O

Anti B-Therapeutic_procedure
- I-Therapeutic_procedure
angiogenic I-Therapeutic_procedure
treatment E-Therapeutic_procedure
with	O
intravitreal	O
aflibercept S-Medication
injections	O
were	O
administered	O
with	O
a	O
treat B-Detailed_description
- I-Detailed_description
and I-Detailed_description
- I-Detailed_description
extend I-Detailed_description
regimen E-Detailed_description
.	O

OCT S-Diagnostic_procedure
angiograms S-Detailed_description
(	O
Fig	O
.	O
1	O
)	O
showed	O
noticeable B-Lab_value
reduction E-Lab_value
in	O
CNV B-Diagnostic_procedure
flow I-Diagnostic_procedure
area E-Diagnostic_procedure
by	O
1	O
-	O
2	O
days	O
post	O
injection	O
,	O
with	O
continued B-Lab_value
reduction E-Lab_value
at	O
1	O
week	O
and	O
2	O
weeks	O
.	O

CNV B-Diagnostic_procedure
flow I-Diagnostic_procedure
area E-Diagnostic_procedure
and	O
vessel B-Diagnostic_procedure
density E-Diagnostic_procedure
were	O
reduced S-Lab_value
,	O
probably	O
due	O
to	O
the	O
decreased	O
flow	O
or	O
temporary	O
closure	O
of	O
the	O
smaller	O
anastomoses	O
.	O

Significant S-Severity
re B-Lab_value
- I-Lab_value
appearance E-Lab_value
of	O
CNV S-Disease_disorder
was	O
noticeable	O
at	O
4	O
weeks	O
after	O
the	O
first	O
injection	O
and	O
again	O
at	O
6	O
weeks	O
after	O
the	O
second	O
injection	O
.	O

The	O
vascular	O
pattern	O
of	O
the	O
re B-Detailed_description
- I-Detailed_description
enlarged E-Detailed_description
CNV S-Disease_disorder
(	O
Fig	O
.	O
1A	O
)	O
was	O
very	O
similar	O
to	O
the	O
initial	O
pretreatment	O
CNV	O
,	O
suggesting	O
that	O
the	O
recurrence	O
may	O
be	O
reopening	O
of	O
original	O
channels	O
rather	O
than	O
growth	O
of	O
new	O
vessels	O
.	O

Comparing	O
the	O
CNV	O
network	O
prior	O
to	O
the	O
3rd	O
injection	O
to	O
the	O
baseline	O
,	O
it	O
is	O
notable	O
that	O
there	O
were	O
fewer	O
smaller	O
channels	O
,	O
while	O
the	O
larger	O
caliber	O
channels	O
remained	O
.	O

Quantitative	O
measurements	O
from	O
OCT S-Diagnostic_procedure
angiography S-Detailed_description
(	O
Fig	O
.	O
2A	O
)	O
showed	O
reduction S-Lab_value
in	O
CNV B-Diagnostic_procedure
flow I-Diagnostic_procedure
area E-Diagnostic_procedure
and	O
flow B-Diagnostic_procedure
index E-Diagnostic_procedure
over B-Duration
the I-Duration
first I-Duration
2 I-Duration
weeks E-Duration
with	O
subsequent	O
return	O
.	O

Retinal B-Sign_symptom
thickness E-Sign_symptom
(	O
Fig	O
.	O
2B	O
)	O
showed	O
the	O
fluid	O
resorption	O
over B-Duration
the I-Duration
first I-Duration
4 I-Duration
weeks E-Duration
in	O
the	O
first	O
treatment	O
cycle	O
continuing	O
at	O
least	O
2	O
weeks	O
into	O
the	O
second	O
treatment	O
cycle	O
,	O
at	O
which	O
time	O
no	O
fluid	O
remained	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

But	O
fluid B-Sign_symptom
re I-Sign_symptom
- I-Sign_symptom
accumulated E-Sign_symptom
under B-Biological_structure
the I-Biological_structure
retina E-Biological_structure
6	O
weeks	O
after	O
the	O
2nd	O
injection	O
.	O

Visual B-Diagnostic_procedure
acuity E-Diagnostic_procedure
(	O
Fig	O
.	O
2B	O
)	O
continued B-Lab_value
to I-Lab_value
improve E-Lab_value
over	O
the	O
3	O
treatment	O
cycles	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
73 B-Age
- I-Age
year I-Age
- I-Age
old E-Age
man	O
who	O
had	O
been	O
transferred	O
to	O
our	O
emergency B-Nonbiological_location
room E-Nonbiological_location
due	O
to	O
sudden S-Detailed_description
chest S-Biological_structure
pain S-Sign_symptom
was	O
diagnosed	O
with	O
ST B-Disease_disorder
- I-Disease_disorder
segment I-Disease_disorder
elevation I-Disease_disorder
myocardial I-Disease_disorder
infarction E-Disease_disorder
(	O
STEMI S-Disease_disorder
)	O
.	O

He	O
had	O
no	O
coronary	O
risk	O
factors	O
except	O
for	O
a	O
history	O
of	O
smoking	O
for	O
50	O
years	O
.	O

Primary S-Detailed_description
percutaneous S-Biological_structure
coronary B-Therapeutic_procedure
intervention E-Therapeutic_procedure
was	O
performed	O
,	O
and	O
a	O
long S-Detailed_description
,	O
string B-Shape
- I-Shape
shaped E-Shape
contrast B-Sign_symptom
defect E-Sign_symptom
was	O
observed	O
in	O
the	O
left B-Biological_structure
anterior I-Biological_structure
descending I-Biological_structure
artery E-Biological_structure
(	O
Fig	O
.	O
1A	O
)	O
.	O

Optical B-Diagnostic_procedure
coherence I-Diagnostic_procedure
tomography E-Diagnostic_procedure
(	O
OCT S-Diagnostic_procedure
)	O
imaging	O
revealed	O
an	O
odd S-Detailed_description
,	O
smooth B-Texture
- I-Texture
surfaced E-Texture
50 B-Distance
- I-Distance
mm I-Distance
long E-Distance
object S-Sign_symptom
(	O
Fig	O
.	O
1B	O
)	O
.	O

A	O
long S-Detailed_description
,	O
white S-Color
object S-Sign_symptom
which	O
looked B-Detailed_description
like I-Detailed_description
a I-Detailed_description
parasitic I-Detailed_description
worm E-Detailed_description
was	O
retrieved	O
via	O
intracoronary B-Therapeutic_procedure
aspiration E-Therapeutic_procedure
and	O
revascularization S-Therapeutic_procedure
was	O
successfully B-Lab_value
completed E-Lab_value
since	O
neither	O
plaque B-Sign_symptom
rupture E-Sign_symptom
or	O
the	O
presence	O
of	O
thrombus S-Sign_symptom
was	O
detected	O
by	O
OCT	O
(	O
Fig	O
.	O
1C	O
)	O
.	O

On	O
the	O
eleventh	O
hospital	O
day	O
,	O
transthoracic S-Biological_structure
echocardiography S-Diagnostic_procedure
revealed	O
a	O
new	O
floating S-Detailed_description
object S-Sign_symptom
in	O
the	O
left B-Biological_structure
atrium E-Biological_structure
.	O

Contrast B-Diagnostic_procedure
computed I-Diagnostic_procedure
tomography E-Diagnostic_procedure
revealed	O
a	O
huge S-Detailed_description
7 B-Area
× I-Area
6 I-Area
cm E-Area
mass S-Sign_symptom
that	O
was	O
recognized	O
at	O
admission	O
in	O
the	O
right B-Biological_structure
upper I-Biological_structure
pulmonary I-Biological_structure
lobe E-Biological_structure
with	O
direct B-Detailed_description
pulmonary I-Detailed_description
vein I-Detailed_description
invasion E-Detailed_description
(	O
Fig	O
.	O
1D	O
)	O
.	O

Although	O
the	O
bronchoscopic B-Diagnostic_procedure
findings E-Diagnostic_procedure
were	O
negative	O
for	O
a	O
lung B-Sign_symptom
tumor E-Sign_symptom
,	O
a	O
histopathologic B-Diagnostic_procedure
examination E-Diagnostic_procedure
of	O
the	O
aspirated S-Detailed_description
coronary S-Biological_structure
object	O
revealed	O
pleomorphic S-Detailed_description
lung S-Biological_structure
carcinoma S-Disease_disorder
(	O
Fig	O
.	O
2	O
)	O
.	O

The	O
patient	O
was	O
diagnosed	O
with	O
STEMI S-Disease_disorder
due	O
to	O
coronary S-Biological_structure
embolization S-Sign_symptom
associated	O
with	O
lung S-Biological_structure
carcinoma S-Disease_disorder
.	O

Brain S-Biological_structure
MRI S-Diagnostic_procedure
revealed	O
that	O
the	O
patient	O
had	O
an	O
asymptomatic S-Detailed_description
cerebral S-Biological_structure
infarction S-Sign_symptom
in	O
the	O
right B-Biological_structure
frontal I-Biological_structure
lobe E-Biological_structure
and	O
a	O
small S-Detailed_description
parietal B-Biological_structure
lobe E-Biological_structure
lesion S-Sign_symptom
was	O
diagnosed	O
to	O
be	O
metastasis S-Sign_symptom
.	O

Given	O
all	O
these	O
observations	O
,	O
he	O
was	O
diagnosed	O
with	O
right B-Biological_structure
lung E-Biological_structure
carcinoma S-Disease_disorder
,	O
stage B-Detailed_description
IV E-Detailed_description
(	O
c B-Detailed_description
- I-Detailed_description
T2bN2M1b E-Detailed_description
)	O
.	O

He	O
was	O
treated	O
according	O
to	O
the	O
chemotherapy S-Medication
regimens	O
(	O
carboplatin S-Medication
&	O
paclitaxel S-Medication
)	O
known	O
to	O
be	O
effective	O
for	O
the	O
treatment	O
of	O
advanced	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

He	O
responded	O
to	O
the	O
treatment	O
and	O
showed	O
a	O
good S-Lab_value
clinical B-Diagnostic_procedure
course E-Diagnostic_procedure
afterwards	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Chemotherapy S-Medication
with	O
a	O
total	O
of	O
9 B-Dosage
cycles E-Dosage
of	O
the	O
same	O
regimen	O
was	O
used	O
and	O
the	O
carcinoma B-Diagnostic_procedure
progression E-Diagnostic_procedure
was	O
suppressed S-Lab_value
.	O

He	O
has	O
been	O
doing B-Sign_symptom
well E-Sign_symptom
for	O
more B-Duration
than I-Duration
two I-Duration
years E-Duration
of	O
PCI S-Therapeutic_procedure
and	O
has	O
been	O
followed	O
-	O
up	O
regularly S-Detailed_description
.	O

-DOCSTART- -X- -X- -X- O

We	O
report	O
the	O
case	O
of	O
a	O
68 B-Age
- I-Age
year I-Age
- I-Age
old E-Age
female	O
with	O
no	O
past	O
medical	O
history	O
,	O
presented	O
with	O
an	O
upper B-Biological_structure
gastrointestinal E-Biological_structure
bleeding S-Sign_symptom
and	O
pain S-Sign_symptom
in	O
left B-Biological_structure
upper I-Biological_structure
abdomen E-Biological_structure
.	O

Physical B-Diagnostic_procedure
examination E-Diagnostic_procedure
found	O
a	O
splenomegaly S-Sign_symptom
and	O
signs	O
of	O
portosystemic B-Disease_disorder
collateral I-Disease_disorder
formation E-Disease_disorder
including	O
abdominal B-Biological_structure
wall E-Biological_structure
dilated B-Sign_symptom
veins E-Sign_symptom
and	O
rectal S-Biological_structure
haemorrhoids S-Sign_symptom
.	O

No	O
biological B-Sign_symptom
abnormalities E-Sign_symptom
were	O
noted	O
besides	O
those	O
due	O
to	O
hypersplenism S-Disease_disorder
(	O
anaemia S-Sign_symptom
and	O
thrombocytopenia S-Sign_symptom
)	O
.	O

The	O
patient	O
underwent	O
upper B-Biological_structure
gastrointestinal E-Biological_structure
endoscopy S-Diagnostic_procedure
that	O
showed	O
stage B-Detailed_description
III E-Detailed_description
oesophageal S-Biological_structure
varices S-Sign_symptom
with	O
portal B-Disease_disorder
hypertensive I-Disease_disorder
gastropathy E-Disease_disorder
and	O
red B-Sign_symptom
signs E-Sign_symptom
.	O

Ultrasonography S-Diagnostic_procedure
revealed	O
a	O
fusiform B-Sign_symptom
dilatation E-Sign_symptom
of	O
the	O
portal B-Biological_structure
bifurcation E-Biological_structure
measuring	O
40 B-Distance
mm E-Distance
in	O
diameter	O
with	O
dilated B-Detailed_description
branches E-Detailed_description
;	O
no	O
signs B-Sign_symptom
of I-Sign_symptom
portal I-Sign_symptom
thrombosis E-Sign_symptom
were	O
detected	O
(	O
Figure	O
1	O
)	O
.	O

The	O
portal S-Biological_structure
Doppler B-Diagnostic_procedure
study E-Diagnostic_procedure
showed	O
a	O
normal B-Lab_value
hepatopetal I-Lab_value
flow E-Lab_value
.	O

Other B-Sign_symptom
signs I-Sign_symptom
of I-Sign_symptom
portal I-Sign_symptom
hypertension E-Sign_symptom
were	O
found	O
,	O
including	O
splenomegaly S-Sign_symptom
,	O
repermeation S-Sign_symptom
of	O
the	O
umbilical B-Biological_structure
vein E-Biological_structure
and	O
a	O
splenorenal S-Biological_structure
collateral B-Sign_symptom
circulation E-Sign_symptom
.	O

A	O
complementary	O
angio S-Biological_structure
-	O
CT S-Diagnostic_procedure
allowed	O
a	O
better	O
assessment	O
of	O
the	O
portal	O
system	O
that	O
contained	O
some	O
thin B-Sign_symptom
calcifications E-Sign_symptom
in	O
the	O
aneurysmal B-Biological_structure
wall E-Biological_structure
and	O
the	O
main B-Biological_structure
portal I-Biological_structure
trunk E-Biological_structure
(	O
Figure	O
2	O
,	O
Figure	O
3	O
,	O
Figure	O
4	O
)	O
.	O

Other B-Sign_symptom
signs I-Sign_symptom
of I-Sign_symptom
portal I-Sign_symptom
hypertension E-Sign_symptom
were	O
noted	O
such	O
as	O
oesophageal S-Biological_structure
and	O
gastric S-Biological_structure
varices S-Sign_symptom
,	O
parietal S-Biological_structure
collateral B-Sign_symptom
circulation E-Sign_symptom
associated	O
to	O
ultrasonography	O
findings	O
.	O

Liver B-Disease_disorder
cirrhosis E-Disease_disorder
was	O
confirmed	O
by	O
transcient B-Diagnostic_procedure
elastometry E-Diagnostic_procedure
and	O
biopsy S-Diagnostic_procedure
.	O

-DOCSTART- -X- -X- -X- O

This	O
young S-Age
boy	O
is	O
the	O
first	O
child	O
of	O
healthy B-Detailed_description
non I-Detailed_description
- I-Detailed_description
consanguineous E-Detailed_description
,	O
white	O
British	O
parents	O
.	O

He	O
was	O
born	O
at B-Detailed_description
term E-Detailed_description
following	O
an	O
uneventful B-Detailed_description
pregnancy E-Detailed_description
weighing	O
3132 B-Weight
g E-Weight
(	O
9th	O
-	O
25th	O
centile	O
)	O
.	O

Early B-Diagnostic_procedure
development E-Diagnostic_procedure
was	O
thought	O
to	O
be	O
normal S-Lab_value
.	O

At	O
approximately	O
6	O
months	O
of	O
age	O
he	O
developed	O
tonic B-Detailed_description
upward E-Detailed_description
eye B-Sign_symptom
deviation E-Sign_symptom
associated	O
with	O
flexion S-Sign_symptom
of	O
his	O
arms S-Biological_structure
and	O
neck S-Biological_structure
consistent	O
with	O
infantile B-Disease_disorder
spasms E-Disease_disorder
.	O

An	O
electroencephalograph S-Diagnostic_procedure
(	O
EEG S-Diagnostic_procedure
)	O
at	O
this	O
time	O
was	O
grossly B-Lab_value
abnormal E-Lab_value
(	O
hypsarrhythmia S-Sign_symptom
)	O
and	O
strongly	O
supported	O
a	O
diagnosis	O
of	O
West B-Disease_disorder
Syndrome E-Disease_disorder
.	O

Cranial S-Biological_structure
MRI S-Diagnostic_procedure
was	O
reported	O
as	O
normal S-Lab_value
.	O

Prednisolone S-Medication
was	O
prescribed	O
and	O
treated	O
the	O
seizures S-Sign_symptom
effectively	O
.	O

Steroids S-Medication
were	O
weaned	O
over B-Duration
6 I-Duration
weeks E-Duration
and	O
he	O
remained	O
seizure S-Sign_symptom
free	O
for	O
a	O
further B-Duration
6 I-Duration
months E-Duration
.	O

By	O
the	O
age	O
of	O
1	O
year	O
,	O
it	O
was	O
apparent	O
that	O
his	O
early	O
developmental B-Diagnostic_procedure
progress E-Diagnostic_procedure
was	O
not B-Lab_value
being I-Lab_value
maintained E-Lab_value
and	O
that	O
he	O
was	O
functioning	O
at	O
the	O
6 B-Lab_value
- I-Lab_value
8 I-Lab_value
month E-Lab_value
developmental B-Diagnostic_procedure
stage E-Diagnostic_procedure
.	O

Seizures S-Sign_symptom
returned	O
shortly	O
after	O
his	O
first	O
birthday	O
and	O
were	O
prolonged S-Detailed_description
,	O
frequent S-Detailed_description
and	O
on B-Detailed_description
occasion I-Detailed_description
focal E-Detailed_description
,	O
involving	O
his	O
right B-Biological_structure
arm E-Biological_structure
,	O
leg S-Biological_structure
and	O
right B-Biological_structure
side I-Biological_structure
of I-Biological_structure
face E-Biological_structure
.	O

Clonazepam S-Medication
briefly	O
improved	O
seizure S-Sign_symptom
frequency	O
,	O
but	O
subsequently	O
his	O
epilepsy S-Disease_disorder
has	O
proved	O
refractory B-Detailed_description
to I-Detailed_description
various I-Detailed_description
combinations I-Detailed_description
of I-Detailed_description
anticonvulsant I-Detailed_description
therapy E-Detailed_description
.	O

Prolonged S-Detailed_description
seizures S-Sign_symptom
of	O
more B-Detailed_description
than I-Detailed_description
60 I-Detailed_description
min E-Detailed_description
have	O
been	O
associated	O
with	O
a	O
stepwise B-Lab_value
regression E-Lab_value
in	O
his	O
neurodevelopment S-Diagnostic_procedure
.	O

Seizure S-Sign_symptom
semiology	O
is	O
now	O
predominantly	O
one	O
of	O
epilepsia B-Disease_disorder
partialis I-Disease_disorder
continua E-Disease_disorder
involving	O
the	O
right B-Biological_structure
side I-Biological_structure
of I-Biological_structure
his I-Biological_structure
face E-Biological_structure
,	O
right B-Biological_structure
arm E-Biological_structure
and	O
right B-Biological_structure
leg E-Biological_structure
.	O

The	O
development	O
of	O
focal S-Detailed_description
seizures S-Sign_symptom
and	O
the	O
progressive S-Detailed_description
nature	O
of	O
the	O
condition	O
prompted	O
a	O
second	O
cranial S-Biological_structure
MRI S-Diagnostic_procedure
at	O
the	O
age	O
of	O
2	O
years	O
6	O
months	O
.	O

By	O
contrast	O
with	O
the	O
previous	O
scan	O
,	O
this	O
MRI S-Diagnostic_procedure
revealed	O
symmetrical S-Detailed_description
subcortical B-Biological_structure
white I-Biological_structure
matter E-Biological_structure
lesions S-Sign_symptom
(	O
Fig	O
.	O
1A	O
)	O
with	O
thinning S-Sign_symptom
of	O
the	O
anterior B-Biological_structure
and I-Biological_structure
genu I-Biological_structure
of I-Biological_structure
the I-Biological_structure
corpus I-Biological_structure
callosum E-Biological_structure
(	O
Fig	O
.	O
1B	O
)	O
.	O

On	O
examination S-Diagnostic_procedure
,	O
the	O
patient	O
had	O
small S-Detailed_description
,	O
round S-Shape
,	O
anteriorly B-Detailed_description
rotated E-Detailed_description
ears S-Biological_structure
and	O
a	O
broad S-Detailed_description
nasal B-Biological_structure
root E-Biological_structure
.	O

He	O
demonstrated	O
no S-Lab_value
visual B-Diagnostic_procedure
awareness E-Diagnostic_procedure
but	O
startled B-Sign_symptom
to I-Sign_symptom
loud I-Sign_symptom
noise E-Sign_symptom
.	O

Tone S-Diagnostic_procedure
was	O
increased S-Lab_value
in	O
all B-Biological_structure
4 I-Biological_structure
limbs E-Biological_structure
with	O
internal B-Sign_symptom
rotation E-Sign_symptom
of	O
both B-Biological_structure
legs I-Biological_structure
at I-Biological_structure
the I-Biological_structure
hips E-Biological_structure
.	O

Reflexes S-Diagnostic_procedure
were	O
pathologically B-Lab_value
brisk E-Lab_value
.	O

Brief S-Detailed_description
myoclonic B-Sign_symptom
jerks E-Sign_symptom
were	O
evident	O
throughout	O
the	O
examination	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
33 B-Age
- I-Age
year I-Age
- I-Age
old E-Age
Moroccan	O
man	O
with	O
a	O
5 B-Duration
- I-Duration
month E-Duration
history	O
of	O
recurring S-Detailed_description
sinusitis S-Disease_disorder
presented	O
with	O
temperature S-Sign_symptom
,	O
myalgia S-Sign_symptom
,	O
cough S-Sign_symptom
,	O
and	O
hemoptysis S-Sign_symptom
.	O

Thoracic S-Biological_structure
physical B-Diagnostic_procedure
examination E-Diagnostic_procedure
revealed	O
reduced S-Lab_value
vesicular B-Diagnostic_procedure
murmur E-Diagnostic_procedure
,	O
and	O
chest S-Biological_structure
X B-Diagnostic_procedure
- I-Diagnostic_procedure
ray E-Diagnostic_procedure
showed	O
bilateral B-Detailed_description
diffuse E-Detailed_description
alveolar S-Biological_structure
infiltrates S-Sign_symptom
.	O

Laboratory B-Diagnostic_procedure
analyses E-Diagnostic_procedure
showed	O
elevation S-Lab_value
of	O
acute B-Diagnostic_procedure
- I-Diagnostic_procedure
phase I-Diagnostic_procedure
proteins E-Diagnostic_procedure
(	O
CRP S-Diagnostic_procedure
26 B-Lab_value
mg I-Lab_value
/ I-Lab_value
dL E-Lab_value
)	O
and	O
creatinine S-Diagnostic_procedure
(	O
1 B-Lab_value
. I-Lab_value
2 I-Lab_value
mg I-Lab_value
/ I-Lab_value
dL E-Lab_value
)	O
with	O
nonnephrotic S-Detailed_description
proteinuria S-Sign_symptom
and	O
microscopic B-Detailed_description
glomerular E-Detailed_description
hematuria S-Sign_symptom
.	O

An	O
antibiotic B-Medication
therapy E-Medication
for	O
community B-Detailed_description
acquired E-Detailed_description
and	O
atypical S-Detailed_description
pneumoniae S-Disease_disorder
with	O
levofloxacin S-Medication
500 B-Dosage
mg I-Dosage
daily E-Dosage
iv	O
was	O
established	O
,	O
but	O
on	O
the	O
3rd	O
day	O
from	O
admission	O
the	O
patient	O
developed	O
respiratory B-Disease_disorder
failure E-Disease_disorder
unresponsive	O
to	O
noninvasive S-Detailed_description
ventilation S-Therapeutic_procedure
and	O
had	O
to	O
be	O
intubated S-Therapeutic_procedure
.	O

White S-Color
lung S-Biological_structure
with	O
consolidations S-Sign_symptom
and	O
ground B-Sign_symptom
glass I-Sign_symptom
areas E-Sign_symptom
at	O
computed B-Diagnostic_procedure
tomography E-Diagnostic_procedure
scan	O
(	O
Fig	O
.	O
1	O
)	O
,	O
diffuse S-Detailed_description
airways S-Biological_structure
bleeding S-Sign_symptom
at	O
fiberoptic S-Detailed_description
bronchoscopy S-Diagnostic_procedure
,	O
mild S-Severity
normocytic S-Detailed_description
anemia S-Diagnostic_procedure
(	O
9 B-Lab_value
g I-Lab_value
/ I-Lab_value
dL E-Lab_value
)	O
,	O
and	O
ANCA B-Diagnostic_procedure
- I-Diagnostic_procedure
PR3 E-Diagnostic_procedure
positivity S-Lab_value
(	O
18 B-Lab_value
. I-Lab_value
9 I-Lab_value
U I-Lab_value
/ I-Lab_value
mL E-Lab_value
)	O
were	O
consistent	O
with	O
the	O
diagnosis	O
of	O
GPA S-Disease_disorder
.	O

Despite	O
maximal S-Detailed_description
ventilatory B-Therapeutic_procedure
support E-Therapeutic_procedure
,	O
gas B-Diagnostic_procedure
exchange E-Diagnostic_procedure
did B-Lab_value
not I-Lab_value
improve E-Lab_value
(	O
pH S-Diagnostic_procedure
7 B-Lab_value
. I-Lab_value
33 E-Lab_value
,	O
PaO2 S-Diagnostic_procedure
71 B-Lab_value
mm I-Lab_value
Hg E-Lab_value
,	O
PaCO2 S-Diagnostic_procedure
51 B-Lab_value
mm I-Lab_value
Hg E-Lab_value
,	O
HCO3 S-Diagnostic_procedure
-	O
25 B-Lab_value
mmol I-Lab_value
/ I-Lab_value
L E-Lab_value
,	O
SaO2 S-Diagnostic_procedure
94 B-Lab_value
% E-Lab_value
)	O
requiring	O
extracorporeal B-Therapeutic_procedure
membrane I-Therapeutic_procedure
oxygenation E-Therapeutic_procedure
(	O
ECMO S-Therapeutic_procedure
)	O
.	O

Treatment	O
with	O
high B-Dosage
- I-Dosage
dose E-Dosage
methylprednisolone S-Medication
(	O
1 B-Dosage
g I-Dosage
daily E-Dosage
for	O
3 B-Duration
days E-Duration
and	O
1 B-Dosage
mg I-Dosage
/ I-Dosage
kg I-Dosage
daily E-Dosage
thereafter	O
)	O
,	O
cyclophosphamide S-Medication
(	O
1 B-Dosage
. I-Dosage
2 I-Dosage
g I-Dosage
/ I-Dosage
pulse I-Dosage
every I-Dosage
2 I-Dosage
weeks I-Dosage
for I-Dosage
the I-Dosage
1st I-Dosage
3 I-Dosage
pulses E-Dosage
,	O
followed	O
by	O
infusions	O
every B-Dosage
3 I-Dosage
weeks I-Dosage
for I-Dosage
the I-Dosage
next I-Dosage
2 I-Dosage
pulses E-Dosage
)	O
,	O
and	O
plasma B-Therapeutic_procedure
exchange E-Therapeutic_procedure
(	O
PE S-Therapeutic_procedure
)	O
,	O
according	O
to	O
European B-Detailed_description
vasculitis I-Detailed_description
study I-Detailed_description
group I-Detailed_description
recommendations E-Detailed_description
,	O
[	O
4	O
]	O
was	O
immediately	O
started	O
with	O
respiratory S-Diagnostic_procedure
improvement S-Lab_value
that	O
allowed	O
ECMO S-Therapeutic_procedure
and	O
orotracheal B-Therapeutic_procedure
tube E-Therapeutic_procedure
withdrawal	O
and	O
subsequent	O
discharge	O
from	O
intensive B-Nonbiological_location
care I-Nonbiological_location
unit E-Nonbiological_location
.	O

After	O
9	O
days	O
from	O
the	O
beginning	O
of	O
treatment	O
ANCA B-Diagnostic_procedure
- I-Diagnostic_procedure
PR3 E-Diagnostic_procedure
levels	O
normalized S-Lab_value
(	O
3 B-Lab_value
U I-Lab_value
/ I-Lab_value
mL E-Lab_value
)	O
.	O

Two	O
months	O
later	O
,	O
after	O
the	O
5th B-Detailed_description
bolus E-Detailed_description
of	O
cyclophosphamide S-Medication
and	O
with	O
prednisone S-Medication
0 B-Dosage
. I-Dosage
3 I-Dosage
mg I-Dosage
/ I-Dosage
kg I-Dosage
/ I-Dosage
day E-Dosage
,	O
the	O
patient	O
complained	O
arthromyalgia S-Sign_symptom
and	O
testicular S-Biological_structure
pain S-Sign_symptom
with	O
edema S-Sign_symptom
,	O
cough S-Sign_symptom
,	O
and	O
shortness B-Sign_symptom
of I-Sign_symptom
breath E-Sign_symptom
:	O
laboratory B-Diagnostic_procedure
data E-Diagnostic_procedure
showed	O
worsening S-Lab_value
of	O
renal B-Diagnostic_procedure
function E-Diagnostic_procedure
,	O
mild S-Severity
anemia S-Sign_symptom
,	O
and	O
hypoxemia S-Sign_symptom
(	O
PaO2 S-Diagnostic_procedure
61 B-Lab_value
mm I-Lab_value
Hg E-Lab_value
)	O
.	O

Epididymitis S-Disease_disorder
was	O
confirmed	O
by	O
ultrasound S-Diagnostic_procedure
.	O

Because	O
of	O
rapidly B-Detailed_description
progressive E-Detailed_description
renal B-Disease_disorder
failure E-Disease_disorder
(	O
estimated	O
glomerular B-Diagnostic_procedure
filtration I-Diagnostic_procedure
rate E-Diagnostic_procedure
35 B-Lab_value
mL I-Lab_value
/ I-Lab_value
min E-Lab_value
)	O
renal S-Biological_structure
biopsy S-Diagnostic_procedure
was	O
performed	O
and	O
showed	O
prominent S-Severity
intracapillary S-Biological_structure
and	O
extracapillary S-Biological_structure
proliferation S-Sign_symptom
,	O
with	O
the	O
formation	O
of	O
some	O
fibrocellular B-Sign_symptom
crescents E-Sign_symptom
and	O
focal S-Detailed_description
capillary S-Biological_structure
necrosis S-Sign_symptom
(	O
Fig	O
.	O
2	O
)	O
.	O

Lung S-Biological_structure
computed B-Diagnostic_procedure
tomography E-Diagnostic_procedure
-	O
scan	O
and	O
fiberoptic S-Detailed_description
bronchoscopy S-Diagnostic_procedure
also	O
confirmed	O
alveolar S-Biological_structure
hemorrhage S-Sign_symptom
relapse S-Detailed_description
.	O

Treatment	O
with	O
high B-Dosage
- I-Dosage
dose E-Dosage
methylprednisolone S-Medication
(	O
1 B-Dosage
g I-Dosage
daily E-Dosage
for	O
3 B-Duration
consecutive I-Duration
days E-Duration
)	O
and	O
rituximab S-Medication
(	O
375 B-Dosage
mg I-Dosage
/ I-Dosage
m2 I-Dosage
weekly E-Dosage
for	O
4 B-Duration
weeks E-Duration
)	O
was	O
started	O
with	O
rapid	O
resolution	O
of	O
urologic S-Biological_structure
and	O
pulmonary S-Biological_structure
involvement S-Sign_symptom
but	O
delayed S-Detailed_description
and	O
partial B-Lab_value
improvement E-Lab_value
of	O
renal B-Diagnostic_procedure
function E-Diagnostic_procedure
.	O

At	O
a	O
1	O
-	O
year	O
follow	O
-	O
up	O
,	O
the	O
patient	O
is	O
alive S-Sign_symptom
and	O
under	O
treatment	O
with	O
azathioprine S-Medication
(	O
150 B-Dosage
mg I-Dosage
daily E-Dosage
)	O
and	O
prednisone S-Medication
(	O
15 B-Dosage
mg I-Dosage
daily E-Dosage
)	O
.	O

Renal B-Diagnostic_procedure
function E-Diagnostic_procedure
has	O
markedly B-Lab_value
improved E-Lab_value
(	O
estimated	O
glomerular B-Diagnostic_procedure
filtration I-Diagnostic_procedure
rate E-Diagnostic_procedure
94 B-Lab_value
mL I-Lab_value
/ I-Lab_value
min E-Lab_value
)	O
same	O
as	O
gas B-Diagnostic_procedure
- I-Diagnostic_procedure
exchange E-Diagnostic_procedure
(	O
pH S-Diagnostic_procedure
7 B-Lab_value
. I-Lab_value
42 E-Lab_value
,	O
PaO2 S-Diagnostic_procedure
86 B-Lab_value
mm I-Lab_value
Hg E-Lab_value
,	O
PaCO2 S-Diagnostic_procedure
36 B-Lab_value
mm I-Lab_value
Hg E-Lab_value
,	O
HCO3 S-Diagnostic_procedure
-	O
23 B-Lab_value
mmol I-Lab_value
/ I-Lab_value
L E-Lab_value
,	O
SaO2 S-Diagnostic_procedure
95 B-Lab_value
% E-Lab_value
)	O
.	O

The	O
patient	O
signed	O
institutional	O
informed	O
consent	O
form	O
at	O
the	O
time	O
of	O
admission	O
to	O
hospitalization	O
.	O

An	O
approval	O
by	O
ethics	O
committee	O
was	O
not	O
necessary	O
because	O
of	O
the	O
routine	O
health	O
care	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
21 B-Age
- I-Age
year I-Age
- I-Age
old E-Age
male	O
presented	O
with	O
a	O
2 B-Duration
- I-Duration
year E-Duration
history	O
of	O
progressive S-Detailed_description
shortness B-Sign_symptom
of I-Sign_symptom
breath E-Sign_symptom
on	O
exertion S-Detailed_description
and	O
dry B-Sign_symptom
cough E-Sign_symptom
.	O

At	O
physical B-Diagnostic_procedure
examination E-Diagnostic_procedure
,	O
auscultation S-Diagnostic_procedure
of	O
the	O
lungs S-Biological_structure
has	O
revealed	O
random S-Detailed_description
wheezes S-Sign_symptom
and	O
coarse B-Sign_symptom
crackles E-Sign_symptom
.	O

Cardiac S-Biological_structure
auscultation S-Diagnostic_procedure
was	O
normal	O
,	O
and	O
no	O
cyanosis S-Sign_symptom
or	O
peripheral B-Sign_symptom
edema E-Sign_symptom
was	O
observed	O
.	O

There	O
was	O
no	O
history	O
of	O
smoking	O
or	O
previous	O
known	O
pulmonary B-Disease_disorder
disease E-Disease_disorder
.	O

On	O
routine S-Detailed_description
blood B-Diagnostic_procedure
examination E-Diagnostic_procedure
,	O
blood B-Diagnostic_procedure
counts E-Diagnostic_procedure
and	O
serum B-Diagnostic_procedure
chemistries E-Diagnostic_procedure
were	O
found	O
to	O
be	O
normal S-Lab_value
.	O

Arterial B-Diagnostic_procedure
blood I-Diagnostic_procedure
gas I-Diagnostic_procedure
analysis E-Diagnostic_procedure
and	O
echocardiography S-Diagnostic_procedure
showed	O
no B-Lab_value
important I-Lab_value
abnormalities E-Lab_value
.	O

Pulmonary B-Diagnostic_procedure
function I-Diagnostic_procedure
tests E-Diagnostic_procedure
(	O
PFT S-Diagnostic_procedure
)	O
showed	O
a	O
mild S-Severity
restrictive B-Sign_symptom
ventilatory I-Sign_symptom
defect E-Sign_symptom
,	O
with	O
a	O
reduced S-Lab_value
total B-Diagnostic_procedure
lung I-Diagnostic_procedure
capacity E-Diagnostic_procedure
of	O
79 B-Lab_value
% E-Lab_value
(	O
5 B-Lab_value
. I-Lab_value
94 I-Lab_value
L E-Lab_value
)	O
,	O
forced B-Diagnostic_procedure
vital I-Diagnostic_procedure
capacity E-Diagnostic_procedure
of	O
80 B-Lab_value
% E-Lab_value
(	O
4 B-Lab_value
. I-Lab_value
18 I-Lab_value
L E-Lab_value
)	O
and	O
a	O
forced B-Diagnostic_procedure
expiratory I-Diagnostic_procedure
volume I-Diagnostic_procedure
in I-Diagnostic_procedure
one I-Diagnostic_procedure
second E-Diagnostic_procedure
of	O
83 B-Lab_value
% E-Lab_value
(	O
3 B-Lab_value
. I-Lab_value
72 I-Lab_value
L E-Lab_value
)	O
.	O

The	O
sputum S-Biological_structure
was	O
negative S-Lab_value
for	O
acid B-Diagnostic_procedure
- I-Diagnostic_procedure
alcohol I-Diagnostic_procedure
resistant I-Diagnostic_procedure
bacillus E-Diagnostic_procedure
and	O
human B-Diagnostic_procedure
immunodeficiency I-Diagnostic_procedure
virus I-Diagnostic_procedure
testing E-Diagnostic_procedure
was	O
negative S-Lab_value
as	O
well	O
.	O

The	O
chest B-Diagnostic_procedure
plain I-Diagnostic_procedure
films E-Diagnostic_procedure
revealed	O
a	O
diffuse B-Detailed_description
symmetric E-Detailed_description
dense S-Texture
bilateral S-Biological_structure
micronodular B-Sign_symptom
pattern E-Sign_symptom
(	O
Figure	O
1	O
)	O
.	O

Based	O
on	O
this	O
finding	O
,	O
HRCT B-Diagnostic_procedure
scan E-Diagnostic_procedure
was	O
obtained	O
,	O
revealing	O
diffuse	O
ground B-Sign_symptom
glass I-Sign_symptom
attenuation E-Sign_symptom
and	O
septal B-Sign_symptom
thickening E-Sign_symptom
,	O
more	O
pronounced	O
in	O
lower B-Biological_structure
pulmonary I-Biological_structure
regions E-Biological_structure
,	O
with	O
calcifications S-Sign_symptom
along	O
the	O
interlobar B-Biological_structure
septa E-Biological_structure
and	O
subpleural B-Biological_structure
regions E-Biological_structure
.	O

Subpleural S-Biological_structure
cysts S-Sign_symptom
were	O
also	O
noticed	O
(	O
Figure	O
2	O
)	O
.	O

The	O
patient	O
underwent	O
a	O
fiberoptic B-Diagnostic_procedure
bronchoscopy E-Diagnostic_procedure
with	O
bronchoalveolar B-Diagnostic_procedure
lavage E-Diagnostic_procedure
and	O
transbronchial B-Biological_structure
lung E-Biological_structure
biopsy S-Diagnostic_procedure
.	O

The	O
lavage B-Biological_structure
fluid E-Biological_structure
was	O
negative S-Lab_value
for	O
tuberculosis S-Diagnostic_procedure
or	O
fungi S-Diagnostic_procedure
.	O

Microliths S-Sign_symptom
were	O
not	O
found	O
.	O

Histology S-Diagnostic_procedure
revealed	O
round S-Shape
,	O
concentrically B-Detailed_description
laminated E-Detailed_description
microliths S-Sign_symptom
in	O
the	O
alveoli S-Biological_structure
associated	O
with	O
slightly S-Severity
thickened B-Sign_symptom
interstitial I-Sign_symptom
septa E-Sign_symptom
,	O
consistent	O
with	O
the	O
diagnosis	O
of	O
PAM S-Disease_disorder
.	O

-DOCSTART- -X- -X- -X- O

A	O
64 B-Age
- I-Age
year I-Age
- I-Age
old E-Age
man	O
was	O
admitted	O
to	O
the	O
Department B-Nonbiological_location
of I-Nonbiological_location
Gastroenterology E-Nonbiological_location
of	O
the	O
Affiliated B-Nonbiological_location
Hospital I-Nonbiological_location
of I-Nonbiological_location
Qingdao I-Nonbiological_location
University I-Nonbiological_location
Medical I-Nonbiological_location
College I-Nonbiological_location
( I-Nonbiological_location
Qingdao I-Nonbiological_location
, I-Nonbiological_location
China I-Nonbiological_location
) E-Nonbiological_location
due	O
to	O
epigastric S-Biological_structure
pains S-Sign_symptom
.	O

Physical B-Diagnostic_procedure
examination E-Diagnostic_procedure
revealed	O
no	O
palpable	O
mass S-Sign_symptom
,	O
lymphadenopathy S-Sign_symptom
,	O
or	O
organomegaly S-Sign_symptom
.	O

On	O
endoscopy S-Diagnostic_procedure
,	O
several S-Detailed_description
submucosal S-Biological_structure
lesions S-Sign_symptom
were	O
identified	O
in	O
the	O
gastric B-Biological_structure
antrum E-Biological_structure
and	O
the	O
duodenal B-Biological_structure
bulb E-Biological_structure
(	O
Fig	O
.	O
1	O
)	O
.	O

Endoscopic B-Diagnostic_procedure
ultrasonography E-Diagnostic_procedure
(	O
EUS S-Diagnostic_procedure
)	O
(	O
OLYMPUS B-Detailed_description
EUS I-Detailed_description
EU I-Detailed_description
- I-Detailed_description
ME2 E-Detailed_description
,	O
Miniprobe B-Detailed_description
sonography E-Detailed_description
)	O
demonstrated	O
that	O
the	O
lesions S-Sign_symptom
were	O
almost B-Distance
0 I-Distance
. I-Distance
5 I-Distance
- I-Distance
cm E-Distance
homogeneously	O
hypoechoic S-Detailed_description
neoplasms S-Sign_symptom
originating	O
from	O
the	O
submucous B-Biological_structure
layer E-Biological_structure
(	O
Fig	O
.	O
2	O
)	O
and	O
the	O
initial	O
diagnosis	O
was	O
digestive S-Biological_structure
neuroendocrine B-Disease_disorder
tumors E-Disease_disorder
.	O

Computed B-Diagnostic_procedure
tomography E-Diagnostic_procedure
revealed	O
enlarged B-Sign_symptom
lymph I-Sign_symptom
nodes E-Sign_symptom
in	O
multiple	O
regions	O
(	O
mediastinal S-Biological_structure
,	O
retroperitoneal S-Biological_structure
,	O
mesenteric S-Biological_structure
,	O
and	O
inguinal S-Biological_structure
)	O
and	O
intracavitary S-Detailed_description
nodules S-Sign_symptom
in	O
the	O
duodenum S-Biological_structure
.	O

To	O
reach	O
a	O
definitive	O
diagnosis	O
,	O
the	O
patient	O
underwent	O
repeat S-Detailed_description
EUS S-Diagnostic_procedure
and	O
biopsy S-Diagnostic_procedure
was	O
performed	O
.	O

On	O
endoscopy S-Diagnostic_procedure
,	O
a	O
2 B-Area
× I-Area
1 I-Area
- I-Area
cm E-Area
columnar B-Sign_symptom
uplift E-Sign_symptom
in	O
the	O
terminal B-Biological_structure
ileum E-Biological_structure
and	O
multiple S-Detailed_description
submucosal S-Biological_structure
lesions S-Sign_symptom
in	O
the	O
rectum S-Biological_structure
were	O
identified	O
(	O
Fig	O
.	O
3	O
)	O
.	O

EUS S-Diagnostic_procedure
revealed	O
that	O
the	O
lesions S-Sign_symptom
in	O
the	O
terminal B-Biological_structure
ileum E-Biological_structure
were	O
sized	O
1 B-Area
. I-Area
6 I-Area
× I-Area
1 I-Area
. I-Area
2 I-Area
cm E-Area
and	O
the	O
lesions S-Sign_symptom
in	O
the	O
rectum S-Biological_structure
were	O
sized	O
almost	O
0 B-Area
. I-Area
6 I-Area
× I-Area
1 I-Area
. I-Area
0 I-Area
cm E-Area
,	O
they	O
were	O
all	O
homogeneously B-Detailed_description
hypoechoic E-Detailed_description
and	O
originated B-Detailed_description
from I-Detailed_description
the I-Detailed_description
muscularis I-Detailed_description
mucosa I-Detailed_description
layer E-Detailed_description
.	O

Pathological B-Diagnostic_procedure
examination E-Diagnostic_procedure
of	O
the	O
biopsied	O
specimens	O
from	O
the	O
lesions S-Sign_symptom
of	O
the	O
rectum S-Biological_structure
showed	O
diffuse	O
lymphomatous B-Detailed_description
proliferation E-Detailed_description
and	O
dense B-Detailed_description
infiltration E-Detailed_description
by	O
monomorphic B-Biological_structure
, I-Biological_structure
small I-Biological_structure
cleaved I-Biological_structure
cells I-Biological_structure
with I-Biological_structure
irregularly I-Biological_structure
shaped I-Biological_structure
nuclei E-Biological_structure
(	O
Fig	O
.	O
4	O
)	O
.	O

On	O
immunohistochemical B-Diagnostic_procedure
analysis E-Diagnostic_procedure
,	O
the	O
cells	O
were	O
positive S-Lab_value
for	O
cyclin B-Diagnostic_procedure
D1 E-Diagnostic_procedure
,	O
CD20 S-Diagnostic_procedure
,	O
CD21 S-Diagnostic_procedure
,	O
SOX B-Diagnostic_procedure
- I-Diagnostic_procedure
11 E-Diagnostic_procedure
,	O
and	O
Bcl B-Diagnostic_procedure
- I-Diagnostic_procedure
2 E-Diagnostic_procedure
,	O
but	O
negative S-Lab_value
for	O
CD3 S-Diagnostic_procedure
and	O
CD10 S-Diagnostic_procedure
,	O
which	O
was	O
compatible	O
with	O
the	O
diagnosis	O
of	O
MCL S-Disease_disorder
.	O

Ki B-Diagnostic_procedure
- I-Diagnostic_procedure
67 I-Diagnostic_procedure
staining E-Diagnostic_procedure
revealed	O
a	O
proliferative B-Lab_value
index I-Lab_value
of I-Lab_value
30 I-Lab_value
% E-Lab_value
.	O

Based	O
on	O
these	O
findings	O
,	O
the	O
diagnosis	O
of	O
Ann B-Lab_value
Arbor I-Lab_value
stage I-Lab_value
IV E-Lab_value
MCL S-Disease_disorder
was	O
confirmed	O
.	O

The	O
patient	O
was	O
referred	O
for	O
combination	O
chemotherapy S-Medication
with	O
rituximab S-Medication
,	O
cyclophosphamide S-Medication
,	O
doxorubicin S-Medication
,	O
vincristine S-Medication
,	O
and	O
prednisone S-Medication
(	O
R B-Medication
- I-Medication
CHOP I-Medication
regimen E-Medication
)	O
.	O

The	O
patient	O
has	O
been	O
in	O
remission S-Sign_symptom
clinically	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
75 B-Age
- I-Age
year I-Age
- I-Age
old E-Age
man	O
was	O
referred	O
to	O
our	O
hospital S-Nonbiological_location
for	O
the	O
evaluation	O
of	O
dysphagia S-Sign_symptom
for	O
9 B-Duration
months E-Duration
.	O

He	O
had	O
associated	O
symptoms	O
of	O
nausea S-Sign_symptom
and	O
vomiting S-Sign_symptom
but	O
denied	O
hematemesis S-Sign_symptom
,	O
hematochezia S-Sign_symptom
,	O
lethargy S-Sign_symptom
,	O
and	O
dyspnea S-Sign_symptom
.	O

He	O
was	O
an	O
active	O
smoker	O
and	O
consumed	O
alcohol	O
for	O
30	O
years	O
.	O

Physical B-Diagnostic_procedure
examination E-Diagnostic_procedure
revealed	O
no	O
peripheral S-Detailed_description
lymphadenopathy S-Sign_symptom
,	O
thyromegaly S-Sign_symptom
,	O
ascites S-Sign_symptom
,	O
or	O
mass S-Sign_symptom
in	O
the	O
abdomen S-Biological_structure
.	O

Laboratory B-Diagnostic_procedure
data E-Diagnostic_procedure
were	O
normal S-Lab_value
:	O
HBs B-Diagnostic_procedure
- I-Diagnostic_procedure
Ag E-Diagnostic_procedure
negative S-Lab_value
,	O
HIV S-Diagnostic_procedure
negative S-Lab_value
,	O
and	O
syphilis S-Diagnostic_procedure
negative S-Lab_value
.	O

Test	O
for	O
serum B-Diagnostic_procedure
antibody I-Diagnostic_procedure
against I-Diagnostic_procedure
Helicobacter I-Diagnostic_procedure
pylori E-Diagnostic_procedure
was	O
negative S-Lab_value
.	O

Chest S-Biological_structure
computed B-Diagnostic_procedure
tomography E-Diagnostic_procedure
(	O
CT S-Diagnostic_procedure
)	O
was	O
notable	O
for	O
a	O
huge B-Detailed_description
well I-Detailed_description
- I-Detailed_description
circumscribed E-Detailed_description
and	O
homogeneous S-Detailed_description
cylindrical S-Shape
mesenchymal S-Detailed_description
neoplasm S-Sign_symptom
measuring	O
15 B-Volume
. I-Volume
5 I-Volume
× I-Volume
5 I-Volume
. I-Volume
9 I-Volume
× I-Volume
4 I-Volume
. I-Volume
0 I-Volume
cm E-Volume
in	O
lower B-Biological_structure
and I-Biological_structure
middle I-Biological_structure
esophagus E-Biological_structure
with	O
mild B-Detailed_description
contrast I-Detailed_description
enhancement E-Detailed_description
(	O
Fig	O
.	O
1A	O
)	O
.	O

CT S-Diagnostic_procedure
revealed	O
no	O
abnormalities S-Sign_symptom
in	O
the	O
lungs S-Biological_structure
,	O
heart S-Biological_structure
,	O
ribs S-Biological_structure
,	O
or	O
mediastinum S-Biological_structure
.	O

Endoscopic B-Diagnostic_procedure
examination E-Diagnostic_procedure
showed	O
a	O
submucosal S-Detailed_description
lesion S-Sign_symptom
in	O
the	O
esophagus S-Biological_structure
starting	O
at	O
20 B-Distance
cm I-Distance
from I-Distance
the I-Distance
incisor I-Distance
teeth E-Distance
extending	O
up B-Biological_structure
to I-Biological_structure
the I-Biological_structure
cardia E-Biological_structure
(	O
Fig	O
.	O
1B	O
)	O
.	O

Endoscopic B-Diagnostic_procedure
ultrasonography E-Diagnostic_procedure
(	O
EUS S-Diagnostic_procedure
)	O
revealed	O
hypoechoic S-Detailed_description
lesion S-Sign_symptom
with	O
a	O
clear B-Detailed_description
boundary E-Detailed_description
located	O
in	O
the	O
4th B-Detailed_description
layer E-Detailed_description
.	O

The	O
mass	O
appeared	O
as	O
a	O
benign B-Sign_symptom
tumor E-Sign_symptom
and	O
was	O
preoperatively	O
diagnosed	O
as	O
esophageal B-Disease_disorder
leiomyoma E-Disease_disorder
based	O
on	O
chest	O
CT	O
,	O
endoscopic	O
examination	O
,	O
and	O
EUS	O
findings	O
.	O

Endoscopic B-Detailed_description
mucosal E-Detailed_description
resection S-Therapeutic_procedure
or	O
endoscopic B-Detailed_description
submucosal E-Detailed_description
resection S-Therapeutic_procedure
was	O
not	O
possible	O
because	O
of	O
large	O
size	O
.	O

Hence	O
,	O
surgical S-Detailed_description
resection S-Therapeutic_procedure
was	O
planned	O
and	O
informed	O
written	O
consent	O
was	O
taken	O
.	O

The	O
patient	O
underwent	O
thoracoscopic B-Detailed_description
- I-Detailed_description
assisted E-Detailed_description
resection S-Therapeutic_procedure
of	O
the	O
mass	O
with	O
gastroesophageal S-Detailed_description
anastomosis S-Therapeutic_procedure
,	O
thoracic B-Biological_structure
duct E-Biological_structure
ligation S-Therapeutic_procedure
,	O
and	O
jejunostomy S-Therapeutic_procedure
.	O

Postoperative B-Therapeutic_procedure
course E-Therapeutic_procedure
was	O
uneventful S-Lab_value
.	O

Grossly	O
,	O
a	O
spindle B-Shape
shaped E-Shape
lump S-Sign_symptom
measuring	O
14 B-Volume
× I-Volume
3 I-Volume
. I-Volume
5 I-Volume
× I-Volume
2 I-Volume
. I-Volume
5 I-Volume
cm E-Volume
,	O
was	O
observed	O
in	O
the	O
resected	O
esophagus S-Biological_structure
,	O
which	O
grew	O
into	O
the	O
esophageal B-Biological_structure
lumen E-Biological_structure
and	O
blocked S-Sign_symptom
most	O
of	O
lumen S-Biological_structure
.	O

This	O
lump	O
located	O
in	O
the	O
submucosa S-Biological_structure
was	O
covered B-Detailed_description
with I-Detailed_description
intact I-Detailed_description
mucosa E-Detailed_description
,	O
without	O
erosion S-Sign_symptom
,	O
ulcer S-Disease_disorder
,	O
and	O
hemorrhage S-Disease_disorder
.	O

Its	O
cut	O
surface	O
was	O
homogenously B-Color
white E-Color
to	O
grayish B-Color
- I-Color
white E-Color
in	O
color	O
.	O

Histological B-Diagnostic_procedure
examination E-Diagnostic_procedure
using	O
hematoxylin S-Diagnostic_procedure
and	O
eosin B-Diagnostic_procedure
staining E-Diagnostic_procedure
revealed	O
that	O
tumor	O
was	O
covered B-Detailed_description
with I-Detailed_description
intact I-Detailed_description
squamous I-Detailed_description
epithelium E-Detailed_description
,	O
arising	O
from B-Biological_structure
the I-Biological_structure
submucosal I-Biological_structure
layer E-Biological_structure
and	O
expanding	O
in	O
to	O
the	O
muscular B-Biological_structure
layer E-Biological_structure
.	O

The	O
tumor	O
was	O
composed B-Detailed_description
of I-Detailed_description
many I-Detailed_description
nodules I-Detailed_description
of I-Detailed_description
varying I-Detailed_description
sizes I-Detailed_description
separated I-Detailed_description
by I-Detailed_description
collagen I-Detailed_description
fibers E-Detailed_description
.	O

Numerous B-Detailed_description
cytoplasm I-Detailed_description
- I-Detailed_description
rich I-Detailed_description
cells I-Detailed_description
were I-Detailed_description
observed I-Detailed_description
in I-Detailed_description
the I-Detailed_description
collagenous I-Detailed_description
septations I-Detailed_description
with I-Detailed_description
invasive I-Detailed_description
growth I-Detailed_description
pattern E-Detailed_description
(	O
Fig	O
.	O
2A	O
-	O
C	O
)	O
.	O

The	O
nodules B-Detailed_description
were I-Detailed_description
mainly I-Detailed_description
composed I-Detailed_description
of I-Detailed_description
small I-Detailed_description
to I-Detailed_description
mid I-Detailed_description
- I-Detailed_description
sized I-Detailed_description
centrocyte I-Detailed_description
- I-Detailed_description
like I-Detailed_description
or I-Detailed_description
monocyte I-Detailed_description
- I-Detailed_description
like I-Detailed_description
cells I-Detailed_description
arranged I-Detailed_description
in I-Detailed_description
diffuse I-Detailed_description
pattern E-Detailed_description
.	O

These	O
atypical B-Detailed_description
lymphocytes E-Detailed_description
possessed	O
clear B-Detailed_description
boundary E-Detailed_description
,	O
pale B-Detailed_description
cytoplasm E-Detailed_description
,	O
irregular B-Detailed_description
nucleus E-Detailed_description
,	O
and	O
occasional B-Detailed_description
nucleolus E-Detailed_description
(	O
Fig	O
.	O
2D	O
)	O
.	O

Mitosis S-Diagnostic_procedure
was	O
rare S-Lab_value
.	O

No	O
lymphoepithelial S-Detailed_description
lesion S-Sign_symptom
was	O
recognized	O
in	O
the	O
lesion	O
.	O

On	O
immunohistochemical B-Diagnostic_procedure
staining E-Diagnostic_procedure
,	O
epithelium S-Biological_structure
was	O
diffusely B-Lab_value
positive E-Lab_value
for	O
cytokeratin S-Diagnostic_procedure
(	O
Fig	O
.	O
3A	O
)	O
,	O
and	O
the	O
tumor	O
cells	O
were	O
diffusely B-Lab_value
positive E-Lab_value
for	O
cluster B-Diagnostic_procedure
of I-Diagnostic_procedure
differentiation I-Diagnostic_procedure
( I-Diagnostic_procedure
CD I-Diagnostic_procedure
) I-Diagnostic_procedure
20 E-Diagnostic_procedure
,	O
paired B-Diagnostic_procedure
box I-Diagnostic_procedure
5 E-Diagnostic_procedure
(	O
Fig	O
.	O
3B	O
)	O
,	O
and	O
B B-Diagnostic_procedure
- I-Diagnostic_procedure
cell I-Diagnostic_procedure
lymphoma I-Diagnostic_procedure
( I-Diagnostic_procedure
Bcl I-Diagnostic_procedure
) I-Diagnostic_procedure
- I-Diagnostic_procedure
2 E-Diagnostic_procedure
(	O
Fig	O
.	O
3D	O
)	O
.	O

Small B-Biological_structure
deposits I-Biological_structure
of I-Biological_structure
tumor I-Biological_structure
cells E-Biological_structure
,	O
which	O
were	O
distributed	O
mainly B-Detailed_description
in I-Detailed_description
the I-Detailed_description
collagen I-Detailed_description
fibers E-Detailed_description
,	O
were	O
positive S-Lab_value
for	O
multiple B-Diagnostic_procedure
myeloma I-Diagnostic_procedure
oncogene I-Diagnostic_procedure
1 E-Diagnostic_procedure
,	O
CD138 S-Diagnostic_procedure
,	O
and	O
CD43 S-Diagnostic_procedure
.	O

Several B-Biological_structure
tumor I-Biological_structure
cells E-Biological_structure
were	O
also	O
positive S-Lab_value
for	O
CD30 S-Diagnostic_procedure
.	O

Small B-Biological_structure
lymphocytes E-Biological_structure
were	O
positive S-Lab_value
for	O
CD3 S-Diagnostic_procedure
and	O
CD5 S-Diagnostic_procedure
.	O

Follicular B-Biological_structure
dendritic I-Biological_structure
cells E-Biological_structure
were	O
positive S-Lab_value
for	O
CD21 S-Diagnostic_procedure
and	O
CD23 S-Diagnostic_procedure
(	O
Fig	O
.	O
3C	O
)	O
.	O

All B-Biological_structure
cells E-Biological_structure
were	O
negative S-Lab_value
for	O
CyclinD1 S-Diagnostic_procedure
,	O
CD10 S-Diagnostic_procedure
,	O
Bcl B-Diagnostic_procedure
- I-Diagnostic_procedure
6 E-Diagnostic_procedure
,	O
and	O
B B-Diagnostic_procedure
lymphocyte I-Diagnostic_procedure
specific I-Diagnostic_procedure
activation I-Diagnostic_procedure
of I-Diagnostic_procedure
OCT I-Diagnostic_procedure
binding I-Diagnostic_procedure
protein I-Diagnostic_procedure
1 E-Diagnostic_procedure
.	O

These	O
follicular	O
dendritic	O
cells	O
were	O
arranged	O
in	O
nodules	O
in	O
which	O
the	O
tumor	O
cells	O
were	O
relatively	O
evenly	O
distributed	O
.	O

This	O
pattern	O
was	O
suggestive	O
of	O
follicular	O
colonizations	O
seen	O
in	O
MALT B-Disease_disorder
lymphoma E-Disease_disorder
.	O

In	O
this	O
case	O
,	O
gene B-Diagnostic_procedure
rearragements I-Diagnostic_procedure
and I-Diagnostic_procedure
clonality I-Diagnostic_procedure
analysis E-Diagnostic_procedure
of	O
immunoglobulin B-Diagnostic_procedure
heavy I-Diagnostic_procedure
chain I-Diagnostic_procedure
gene E-Diagnostic_procedure
,	O
kappa B-Diagnostic_procedure
light I-Diagnostic_procedure
chain I-Diagnostic_procedure
gene E-Diagnostic_procedure
,	O
and	O
lambda B-Diagnostic_procedure
light I-Diagnostic_procedure
chain I-Diagnostic_procedure
gene E-Diagnostic_procedure
was	O
performed	O
using	O
the	O
IdentiCloneTM B-Detailed_description
IGH I-Detailed_description
/ I-Detailed_description
IGK I-Detailed_description
/ I-Detailed_description
IGL I-Detailed_description
Gene I-Detailed_description
Clonality I-Detailed_description
Assay E-Detailed_description
(	O
InVivoScribe B-Detailed_description
Technologies I-Detailed_description
, I-Detailed_description
CA E-Detailed_description
)	O
.	O

On	O
monoclonal	O
gene	O
rearrangement	O
,	O
1 B-Lab_value
band I-Lab_value
appeared I-Lab_value
within I-Lab_value
150 I-Lab_value
to I-Lab_value
175 I-Lab_value
base I-Lab_value
pairs E-Lab_value
(	O
bp	O
)	O
in	O
heavy	O
chain	O
gene	O
,	O
2 B-Lab_value
discrete I-Lab_value
bands I-Lab_value
within I-Lab_value
225 I-Lab_value
to I-Lab_value
250 I-Lab_value
bp E-Lab_value
in	O
kappa	O
light	O
chain	O
gene	O
,	O
and	O
1 B-Lab_value
band I-Lab_value
within I-Lab_value
125 I-Lab_value
to I-Lab_value
150 I-Lab_value
bp E-Lab_value
in	O
lambda	O
light	O
chain	O
gene	O
(	O
Fig	O
.	O
4	O
)	O
.	O

In	O
addition	O
,	O
no	O
Epstein B-Disease_disorder
- I-Disease_disorder
Barr I-Disease_disorder
virus E-Disease_disorder
was	O
observed	O
in	O
this	O
lymphoma	O
on	O
in B-Diagnostic_procedure
situ I-Diagnostic_procedure
hybridization E-Diagnostic_procedure
using	O
the	O
EB B-Detailed_description
virus I-Detailed_description
- I-Detailed_description
encoded I-Detailed_description
small I-Detailed_description
RNA E-Detailed_description
(	O
Fig	O
.	O
3E	O
,	O
F	O
)	O
.	O

Based	O
on	O
the	O
clinical	O
data	O
,	O
pathological	O
,	O
immunohistochemical	O
,	O
and	O
gene	O
rearragements	O
analysis	O
,	O
final	O
diagnosis	O
of	O
primary S-Detailed_description
esophageal S-Biological_structure
MALT B-Disease_disorder
lymphoma E-Disease_disorder
was	O
made	O
.	O

After	O
the	O
surgical S-Detailed_description
resection S-Therapeutic_procedure
,	O
no	O
additional	O
therapy S-Therapeutic_procedure
in	O
the	O
form	O
of	O
chemotherapy S-Medication
or	O
radiotherapy S-Therapeutic_procedure
was	O
administered	O
.	O

Over	O
the	O
8 B-Duration
months E-Duration
of	O
follow	O
-	O
up	O
,	O
no	O
evidence	O
of	O
recurrence S-Sign_symptom
or	O
metastases S-Sign_symptom
was	O
found	O
on	O
CT S-Diagnostic_procedure
and	O
the	O
patient	O
has	O
been	O
asymptomatic S-Sign_symptom
.	O

Ethical	O
approval	O
for	O
this	O
study	O
was	O
obtained	O
from	O
Medical	O
Ethics	O
Committee	O
of	O
the	O
Third	O
Affiliated	O
Hospital	O
,	O
the	O
Third	O
Military	O
Medical	O
University	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patient	O
for	O
the	O
publication	O
of	O
this	O
case	O
report	O
and	O
the	O
accompanying	O
images	O
.	O

-DOCSTART- -X- -X- -X- O

n	O
March	O
2015	O
,	O
a	O
62 B-Age
- I-Age
year I-Age
- I-Age
old E-Age
woman	O
was	O
admitted	O
to	O
our	O
hospital S-Nonbiological_location
.	O

She	O
complained	O
of	O
progressive S-Detailed_description
visual B-Sign_symptom
disturbance E-Sign_symptom
,	O
which	O
began	O
about	O
4	O
years	O
ago	O
and	O
was	O
treated	O
as	O
cataract S-Disease_disorder
in	O
local B-Nonbiological_location
hospital E-Nonbiological_location
,	O
but	O
no	O
relief S-Sign_symptom
was	O
seen	O
.	O

On	O
the	O
contrary	O
,	O
the	O
symptoms S-Sign_symptom
aggravated	O
half	O
a	O
year	O
ago	O
,	O
together	O
with	O
headache S-Sign_symptom
,	O
left B-Biological_structure
eye E-Biological_structure
pain S-Sign_symptom
,	O
tearing S-Sign_symptom
and	O
increased	O
secretions S-Sign_symptom
,	O
and	O
the	O
computed B-Diagnostic_procedure
tomography E-Diagnostic_procedure
(	O
CT S-Diagnostic_procedure
)	O
scan	O
of	O
the	O
brain S-Biological_structure
in	O
local B-Nonbiological_location
hospital E-Nonbiological_location
showed	O
a	O
sellar B-Biological_structure
region E-Biological_structure
lesion S-Sign_symptom
.	O

Besides	O
,	O
2	O
years	O
earlier	O
,	O
the	O
patient	O
underwent	O
resection S-Therapeutic_procedure
of	O
melanoma S-Disease_disorder
in	O
the	O
left B-Biological_structure
heel E-Biological_structure
(	O
T2N0M0 S-Lab_value
,	O
ki67 B-Lab_value
3 I-Lab_value
- I-Lab_value
5 I-Lab_value
% E-Lab_value
,	O
Stage B-Lab_value
II E-Lab_value
)	O
,	O
followed	O
by	O
resection S-Therapeutic_procedure
of	O
the	O
recurred S-Detailed_description
melanoma S-Disease_disorder
nearby B-Biological_structure
the I-Biological_structure
primary I-Biological_structure
site E-Biological_structure
15	O
months	O
later	O
(	O
T3N3M0 S-Lab_value
,	O
Stage B-Lab_value
III E-Lab_value
)	O
,	O
without	O
lymphadenectomy S-Therapeutic_procedure
.	O

She	O
had	O
no	O
family	O
history	O
of	O
melanoma	O
.	O

On	O
physical B-Diagnostic_procedure
examination E-Diagnostic_procedure
,	O
the	O
patient	O
had	O
bilateral B-Detailed_description
temporal E-Detailed_description
hemianopsia S-Sign_symptom
,	O
the	O
right B-Diagnostic_procedure
finger I-Diagnostic_procedure
counting E-Diagnostic_procedure
was	O
1 B-Lab_value
m E-Lab_value
,	O
and	O
the	O
left B-Diagnostic_procedure
finger I-Diagnostic_procedure
counting E-Diagnostic_procedure
was	O
no B-Lab_value
more I-Lab_value
than I-Lab_value
0 I-Lab_value
. I-Lab_value
5 I-Lab_value
m E-Lab_value
.	O

Enlarged S-Sign_symptom
lymph B-Biological_structure
nodes E-Biological_structure
were	O
palpable	O
in	O
the	O
right B-Biological_structure
groin E-Biological_structure
.	O

On	O
ophthalmologic B-Diagnostic_procedure
examination E-Diagnostic_procedure
,	O
the	O
patient	O
had	O
right B-Diagnostic_procedure
vision E-Diagnostic_procedure
of	O
0 B-Lab_value
. I-Lab_value
4 E-Lab_value
and	O
left B-Diagnostic_procedure
vision E-Diagnostic_procedure
of	O
0 B-Lab_value
. I-Lab_value
08 E-Lab_value
,	O
with	O
the	O
same	O
intraocular B-Diagnostic_procedure
pressure E-Diagnostic_procedure
15 B-Lab_value
mm I-Lab_value
Hg E-Lab_value
bilaterally S-Detailed_description
.	O

The	O
optometry S-Diagnostic_procedure
found	O
the	O
right B-Biological_structure
eye E-Biological_structure
of	O
+6 B-Lab_value
. I-Lab_value
00DS I-Lab_value
/ I-Lab_value
+0 I-Lab_value
. I-Lab_value
25DC I-Lab_value
∗ I-Lab_value
65 I-Lab_value
° E-Lab_value
and	O
the	O
left B-Biological_structure
eye E-Biological_structure
of	O
+6 B-Lab_value
. I-Lab_value
25DS I-Lab_value
/ I-Lab_value
+0 I-Lab_value
. I-Lab_value
50DC I-Lab_value
∗ I-Lab_value
20 I-Lab_value
° E-Lab_value
.	O

The	O
patient	O
had	O
maculopathy S-Disease_disorder
of	O
both B-Biological_structure
eyes E-Biological_structure
and	O
optic B-Disease_disorder
atrophy E-Disease_disorder
of	O
the	O
left B-Biological_structure
eye E-Biological_structure
.	O

Light B-Diagnostic_procedure
reflex E-Diagnostic_procedure
and	O
eye B-Diagnostic_procedure
movement E-Diagnostic_procedure
of	O
both B-Biological_structure
eyes E-Biological_structure
were	O
normal S-Lab_value
.	O

CT S-Diagnostic_procedure
scans	O
of	O
the	O
brain B-Biological_structure
parenchyma E-Biological_structure
,	O
orbital S-Biological_structure
,	O
and	O
chest S-Biological_structure
were	O
unremarkable S-Lab_value
.	O

CT S-Diagnostic_procedure
scan	O
and	O
ultrasound S-Diagnostic_procedure
examination	O
of	O
the	O
abdomen S-Biological_structure
showed	O
hepatic B-Biological_structure
portal E-Biological_structure
and	O
retroperitoneal S-Biological_structure
lymphadenectasis S-Sign_symptom
and	O
enlarged S-Sign_symptom
left B-Biological_structure
lobe I-Biological_structure
of I-Biological_structure
the I-Biological_structure
liver E-Biological_structure
with	O
substantial S-Severity
placeholder S-Detailed_description
lesions S-Sign_symptom
.	O

Ultrasound S-Diagnostic_procedure
examination	O
of	O
bilateral S-Detailed_description
inguinal B-Biological_structure
lymph I-Biological_structure
nodes E-Biological_structure
discovered	O
multiple S-Detailed_description
low B-Sign_symptom
echo I-Sign_symptom
light I-Sign_symptom
groups E-Sign_symptom
,	O
the	O
largest B-Distance
of I-Distance
which I-Distance
was I-Distance
31 I-Distance
mm E-Distance
in	O
diameter	O
,	O
with	O
hilus B-Detailed_description
of I-Detailed_description
the I-Detailed_description
echo E-Detailed_description
and	O
asymmetrical S-Detailed_description
thickening S-Sign_symptom
of	O
the	O
skin S-Biological_structure
.	O

CT S-Diagnostic_procedure
scan	O
of	O
sellar B-Biological_structure
region E-Biological_structure
revealed	O
a	O
crumby S-Texture
mass S-Sign_symptom
,	O
protruding	O
out	O
of	O
the	O
sphenoid B-Biological_structure
sinus E-Biological_structure
,	O
with	O
obscure B-Detailed_description
boundary E-Detailed_description
and	O
bone B-Detailed_description
destruction E-Detailed_description
.	O

And	O
the	O
average S-Detailed_description
CT B-Diagnostic_procedure
value E-Diagnostic_procedure
of	O
the	O
mass S-Sign_symptom
was	O
46 B-Lab_value
HU E-Lab_value
.	O

Sellar B-Biological_structure
region E-Biological_structure
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging E-Diagnostic_procedure
(	O
MRI S-Diagnostic_procedure
)	O
revealed	O
a	O
round S-Shape
mass S-Sign_symptom
of	O
30 B-Distance
mm E-Distance
in	O
diameter	O
in	O
the	O
enlarged B-Biological_structure
sellae E-Biological_structure
(	O
Fig	O
.	O
1A	O
,	O
B	O
)	O
.	O

The	O
mass	O
showed	O
isointense S-Sign_symptom
in	O
T1 B-Diagnostic_procedure
- I-Diagnostic_procedure
weighted I-Diagnostic_procedure
images E-Diagnostic_procedure
(	O
T1 B-Diagnostic_procedure
- I-Diagnostic_procedure
WI E-Diagnostic_procedure
)	O
and	O
T2 B-Diagnostic_procedure
- I-Diagnostic_procedure
weighted I-Diagnostic_procedure
images E-Diagnostic_procedure
(	O
T2 B-Diagnostic_procedure
- I-Diagnostic_procedure
WI E-Diagnostic_procedure
)	O
,	O
with	O
homogeneous S-Detailed_description
enhancement S-Sign_symptom
after	O
Gadolinium B-Detailed_description
- I-Detailed_description
DTPA I-Detailed_description
injection E-Detailed_description
,	O
and	O
dural B-Detailed_description
tail I-Detailed_description
sign E-Detailed_description
was	O
seen	O
.	O

Small	O
foci	O
inside	O
the	O
tumor	O
showed	O
hyperintense B-Sign_symptom
signals E-Sign_symptom
in	O
T1 B-Diagnostic_procedure
- I-Diagnostic_procedure
WI E-Diagnostic_procedure
and	O
hypointense B-Sign_symptom
signals E-Sign_symptom
in	O
T2 B-Diagnostic_procedure
- I-Diagnostic_procedure
WI E-Diagnostic_procedure
,	O
without B-Detailed_description
enhancement E-Detailed_description
.	O

And	O
it	O
was	O
seen	O
that	O
the	O
mass	O
penetrated	O
meninges S-Biological_structure
,	O
surrounded	O
the	O
left B-Biological_structure
internal I-Biological_structure
carotid I-Biological_structure
artery E-Biological_structure
,	O
and	O
was	O
blurred	O
with	O
the	O
left B-Biological_structure
optic I-Biological_structure
nerve E-Biological_structure
.	O

Pituitary B-Biological_structure
stalk E-Biological_structure
became	O
shorter S-Sign_symptom
with	O
a	O
right B-Detailed_description
displacement E-Detailed_description
.	O

Laboratory B-Diagnostic_procedure
findings E-Diagnostic_procedure
revealed	O
increased S-Lab_value
levels	O
of	O
prolactin S-Diagnostic_procedure
(	O
119 B-Lab_value
. I-Lab_value
08 I-Lab_value
μg I-Lab_value
/ I-Lab_value
L E-Lab_value
,	O
normal	O
range	O
5	O
.	O
99	O
-	O
30	O
.	O
04	O
μg	O
/	O
L	O
)	O
and	O
cortisol S-Diagnostic_procedure
(	O
677 B-Lab_value
. I-Lab_value
10 I-Lab_value
nmol I-Lab_value
/ I-Lab_value
L E-Lab_value
,	O
normal	O
range	O
118	O
.	O
60	O
-	O
618	O
.	O
00	O
nmol	O
/	O
L	O
)	O
and	O
decreased S-Lab_value
levels	O
of	O
free B-Diagnostic_procedure
thyroxine E-Diagnostic_procedure
(	O
FT4 S-Diagnostic_procedure
)	O
(	O
6 B-Lab_value
. I-Lab_value
04 I-Lab_value
pmol I-Lab_value
/ I-Lab_value
L E-Lab_value
,	O
normal	O
range	O
12	O
.	O
00	O
-	O
22	O
.	O
00	O
pmol	O
/	O
L	O
)	O
and	O
free B-Diagnostic_procedure
triiodothyronine E-Diagnostic_procedure
(	O
FT3 S-Diagnostic_procedure
)	O
(	O
2 B-Lab_value
. I-Lab_value
09 I-Lab_value
pmol I-Lab_value
/ I-Lab_value
L E-Lab_value
,	O
normal	O
range	O
3	O
.	O
50	O
-	O
6	O
.	O
50	O
pmol	O
/	O
L	O
)	O
.	O

The	O
patient	O
was	O
diagnosed	O
with	O
a	O
giant S-Detailed_description
prolactinoma S-Disease_disorder
.	O

The	O
patient	O
underwent	O
transnasal B-Detailed_description
transsphenoidal E-Detailed_description
surgery S-Therapeutic_procedure
to	O
remove	O
the	O
tumor	O
and	O
relieve	O
the	O
compression	O
of	O
the	O
optic	O
nerve	O
.	O

Intraoperatively	O
,	O
it	O
was	O
seen	O
that	O
the	O
tumor S-Sign_symptom
invaded	O
and	O
filled	O
the	O
left B-Biological_structure
interval I-Biological_structure
of I-Biological_structure
the I-Biological_structure
sphenoid I-Biological_structure
sinus E-Biological_structure
,	O
and	O
part	O
of	O
bone B-Biological_structure
in I-Biological_structure
sellar I-Biological_structure
floor E-Biological_structure
and	O
left B-Biological_structure
side I-Biological_structure
parasellar E-Biological_structure
was	O
destroyed S-Sign_symptom
and	O
absorbed S-Sign_symptom
.	O

A	O
little B-Detailed_description
normal I-Detailed_description
pituitary I-Detailed_description
tissue I-Detailed_description
was I-Detailed_description
seen I-Detailed_description
in I-Detailed_description
the I-Detailed_description
top I-Detailed_description
right E-Detailed_description
of	O
tumor	O
in	O
the	O
sellar B-Biological_structure
turcica E-Biological_structure
.	O

The	O
tumor	O
was	O
reddish B-Color
black E-Color
with	O
extremely B-Detailed_description
rich I-Detailed_description
blood I-Detailed_description
supply E-Detailed_description
and	O
had	O
close B-Detailed_description
adhesion I-Detailed_description
to I-Detailed_description
the I-Detailed_description
surrounding I-Detailed_description
structure E-Detailed_description
.	O

The	O
texture	O
in	O
the	O
center	O
of	O
the	O
tumor	O
was	O
soft S-Texture
and	O
much B-Texture
tougher I-Texture
over I-Texture
the I-Texture
rim E-Texture
.	O

Intraoperative S-Detailed_description
frozen B-Diagnostic_procedure
- I-Diagnostic_procedure
section I-Diagnostic_procedure
examination E-Diagnostic_procedure
found	O
melanin B-Sign_symptom
granules E-Sign_symptom
,	O
and	O
it	O
was	O
considered	O
to	O
be	O
malignant B-Disease_disorder
melanoma E-Disease_disorder
or	O
meningioma S-Disease_disorder
.	O

The	O
tumor	O
cells	O
were	O
composed	O
of	O
eosinophilic B-Detailed_description
staining I-Detailed_description
epithelial I-Detailed_description
cells E-Detailed_description
.	O

Most	O
of	O
cell B-Diagnostic_procedure
nuclei E-Diagnostic_procedure
were	O
round S-Shape
,	O
a	O
few	O
were	O
reniform S-Lab_value
and	O
hippocrepiform S-Lab_value
with	O
evident S-Lab_value
nucleoli S-Diagnostic_procedure
,	O
and	O
nuclear B-Diagnostic_procedure
fission E-Diagnostic_procedure
was	O
seen S-Lab_value
.	O

The	O
tumor	O
showed	O
no	O
evidence	O
of	O
necrosis S-Sign_symptom
(	O
Fig	O
.	O
2	O
)	O
.	O

The	O
tumor	O
was	O
immunopositive S-Lab_value
focally S-Detailed_description
for	O
melanoma B-Diagnostic_procedure
- I-Diagnostic_procedure
specific I-Diagnostic_procedure
markers E-Diagnostic_procedure
such	O
as	O
S B-Diagnostic_procedure
- I-Diagnostic_procedure
100 E-Diagnostic_procedure
,	O
HMB45 S-Diagnostic_procedure
,	O
and	O
Vimentin S-Diagnostic_procedure
,	O
and	O
immunopositive S-Lab_value
for	O
neuroendocrine B-Diagnostic_procedure
tumor I-Diagnostic_procedure
markers E-Diagnostic_procedure
such	O
as	O
CgA S-Diagnostic_procedure
and	O
Syn S-Diagnostic_procedure
(	O
Fig	O
.	O
3	O
)	O
.	O

The	O
Ki67 B-Diagnostic_procedure
index E-Diagnostic_procedure
was	O
3 B-Lab_value
% I-Lab_value
to I-Lab_value
5 I-Lab_value
% E-Lab_value
;	O
it	O
was	O
higher S-Lab_value
in	O
metastatic B-Detailed_description
melanoma I-Detailed_description
than I-Detailed_description
in I-Detailed_description
the I-Detailed_description
adenomatous I-Detailed_description
component E-Detailed_description
.	O

Taken	O
the	O
melanoma	O
history	O
and	O
suspected	O
lymph	O
node	O
and	O
hepatic	O
metastasis	O
into	O
consideration	O
,	O
the	O
patient	O
was	O
diagnosised	O
with	O
MMPA S-Disease_disorder
.	O

After	O
surgery	O
,	O
significant	O
relief S-Lab_value
was	O
seen	O
in	O
visual B-Diagnostic_procedure
field E-Diagnostic_procedure
and	O
headache S-Sign_symptom
,	O
and	O
the	O
level	O
of	O
prolactin S-Diagnostic_procedure
,	O
cortisol S-Diagnostic_procedure
,	O
and	O
FT4 S-Diagnostic_procedure
returned	O
to	O
normal S-Lab_value
with	O
hormone B-Medication
replacement I-Medication
therapy E-Medication
.	O

Because	O
the	O
focal	O
liver	O
lesions	O
and	O
lymphadenectasis	O
did	O
not	O
cause	O
much	O
discomfort S-Sign_symptom
,	O
the	O
patient	O
refused	O
any	O
further	O
surgical B-Therapeutic_procedure
intervention E-Therapeutic_procedure
or	O
other	O
treatment	O
.	O

She	O
was	O
discharged	O
from	O
the	O
hospital S-Nonbiological_location
immediately	O
and	O
was	O
disease S-Disease_disorder
free	O
until	O
2	O
months	O
after	O
the	O
third	O
surgery	O
.	O

The	O
patient	O
successively	O
found	O
new	O
melanoma S-Disease_disorder
metastatic B-Sign_symptom
sites E-Sign_symptom
in	O
the	O
skin B-Biological_structure
of I-Biological_structure
lower I-Biological_structure
left I-Biological_structure
leg E-Biological_structure
,	O
knees	O
,	O
the	O
upper B-Biological_structure
left I-Biological_structure
leg E-Biological_structure
,	O
the	O
left B-Biological_structure
groin E-Biological_structure
and	O
the	O
right B-Biological_structure
groin E-Biological_structure
,	O
and	O
the	O
right B-Biological_structure
leg E-Biological_structure
.	O

At	O
the	O
follow	O
-	O
up	O
in	O
late	O
January	O
2016	O
,	O
the	O
patient	O
could	O
not	O
walk S-Activity
and	O
live B-Activity
by I-Activity
herself E-Activity
and	O
was	O
depressed S-Disease_disorder
.	O

At	O
the	O
latest	O
follow	O
-	O
up	O
,	O
in	O
late	O
January	O
,	O
2017	O
,	O
the	O
patient	O
was	O
alive S-Sign_symptom
with	O
worse	O
symptoms S-Sign_symptom
,	O
she	O
had	O
sensory B-Sign_symptom
deficits E-Sign_symptom
of	O
both B-Biological_structure
legs E-Biological_structure
,	O
which	O
could B-Sign_symptom
not I-Sign_symptom
move E-Sign_symptom
,	O
hyperalgesia S-Sign_symptom
of	O
hands S-Biological_structure
and	O
mouth S-Biological_structure
,	O
impaired B-Sign_symptom
intelligence E-Sign_symptom
,	O
but	O
she	O
lived	O
well	O
with	O
the	O
disease	O
by	O
careful	O
nursing	O
of	O
her	O
daughter	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
23 B-Age
year I-Age
old E-Age
white	O
male	O
with	O
a	O
4 B-Duration
year E-Duration
history	O
of	O
Crohn B-Disease_disorder
` I-Disease_disorder
s I-Disease_disorder
disease E-Disease_disorder
presented	O
with	O
an	O
acute	O
two B-Duration
day E-Duration
history	O
of	O
malaise S-Sign_symptom
,	O
fever S-Sign_symptom
,	O
abdominal S-Biological_structure
pain S-Sign_symptom
,	O
vomiting S-Sign_symptom
and	O
stomal S-Biological_structure
diarrhoea S-Sign_symptom
.	O

He	O
complained	O
of	O
joint S-Biological_structure
pains S-Sign_symptom
affecting	O
the	O
shoulders S-Biological_structure
,	O
elbows S-Biological_structure
,	O
wrists S-Biological_structure
,	O
metacarpophalangeals S-Biological_structure
,	O
knees S-Biological_structure
and	O
ankles S-Biological_structure
.	O

There	O
was	O
also	O
a	O
rash S-Sign_symptom
on	O
the	O
elbows S-Biological_structure
,	O
ankles S-Biological_structure
and	O
feet S-Biological_structure
,	O
which	O
began	O
as	O
erythematous S-Detailed_description
macules S-Sign_symptom
and	O
evolved	O
to	O
vesico B-Detailed_description
- I-Detailed_description
pustular E-Detailed_description
lesions S-Sign_symptom
followed	O
by	O
crusting S-Sign_symptom
.	O

There	O
was	O
no	O
history	O
of	O
sexual	O
exposure	O
or	O
any	O
intercurrent	O
infection S-Sign_symptom
.	O

He	O
was	O
on	O
no B-Medication
regular I-Medication
medication E-Medication
,	O
but	O
had	O
discontinued	O
Pentasa S-Medication
4	O
months	O
earlier	O
.	O

One	O
month	O
earlier	O
he	O
had	O
undergone	O
a	O
laparotomy S-Therapeutic_procedure
to	O
excise	O
a	O
complex B-Detailed_description
ileo I-Detailed_description
- I-Detailed_description
cutaneous E-Detailed_description
fistula S-Sign_symptom
with	O
blind B-Detailed_description
tracts E-Detailed_description
,	O
and	O
two	O
weeks	O
earlier	O
a	O
defunctioning S-Detailed_description
ileostomy S-Therapeutic_procedure
had	O
been	O
created	O
in	O
view	O
of	O
persistent S-Detailed_description
abdominal S-Biological_structure
pain S-Sign_symptom
.	O

The	O
cutaneous S-Biological_structure
fistula S-Sign_symptom
had B-Duration
been I-Duration
present I-Duration
for I-Duration
a I-Duration
year E-Duration
,	O
but	O
was	O
associated	O
with	O
a	O
terminal S-Detailed_description
ileal S-Biological_structure
stricture S-Sign_symptom
and	O
ileo B-Biological_structure
- I-Biological_structure
rectal E-Biological_structure
fistula S-Sign_symptom
of B-Duration
at I-Duration
least I-Duration
2 I-Duration
years I-Duration
duration E-Duration
.	O

His	O
bowel	O
disease	O
had	O
been	O
resistant	O
to	O
immunosuppressive	O
drugs	O
including	O
azathioprine S-Medication
,	O
corticosteroiods S-Medication
and	O
three B-Dosage
infusions E-Dosage
of	O
Infliximab S-Medication
a	O
year	O
earlier	O
.	O

There	O
had	O
been	O
no B-Sign_symptom
extra I-Sign_symptom
- I-Sign_symptom
intestinal I-Sign_symptom
manifestations E-Sign_symptom
.	O

On	O
admission	O
to	O
the	O
hospital S-Nonbiological_location
,	O
he	O
was	O
thin S-Sign_symptom
,	O
afebrile S-Sign_symptom
with	O
a	O
resting S-Detailed_description
tachycardia S-Sign_symptom
of	O
125 B-Lab_value
/ I-Lab_value
minute E-Lab_value
.	O

The	O
rest	O
of	O
the	O
cardio B-Diagnostic_procedure
- I-Diagnostic_procedure
respiratory I-Diagnostic_procedure
examination E-Diagnostic_procedure
was	O
normal S-Lab_value
.	O

The	O
abdomen S-Biological_structure
was	O
minimally S-Severity
tender S-Sign_symptom
around	O
the	O
ileostomy S-Biological_structure
without B-Detailed_description
guarding I-Detailed_description
or I-Detailed_description
rebound I-Detailed_description
tenderness E-Detailed_description
.	O

Examination B-Diagnostic_procedure
of I-Diagnostic_procedure
the I-Diagnostic_procedure
skin E-Diagnostic_procedure
revealed	O
some	O
pustules S-Sign_symptom
and	O
crusts S-Sign_symptom
around	O
the	O
elbows S-Biological_structure
,	O
ankles S-Biological_structure
and	O
feet S-Biological_structure
(	O
Fig	O
1	O
and	O
2	O
)	O
.	O

The B-Other_event
buttocks I-Other_event
were I-Other_event
spared I-Other_event
. E-Other_event

There	O
were	O
clinical	O
signs	O
of	O
synovitis S-Sign_symptom
of	O
the	O
wrists S-Biological_structure
,	O
proximal B-Biological_structure
interphalangeal E-Biological_structure
and	O
metacarpophalangeal B-Biological_structure
joints E-Biological_structure
,	O
and	O
also	O
both B-Biological_structure
ankles E-Biological_structure
.	O

Results	O
of	O
the	O
laboratory B-Diagnostic_procedure
tests E-Diagnostic_procedure
showed	O
a	O
haemoglobin S-Diagnostic_procedure
of	O
13 B-Lab_value
. I-Lab_value
1 I-Lab_value
gm I-Lab_value
/ I-Lab_value
dl E-Lab_value
,	O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
count E-Diagnostic_procedure
15 B-Lab_value
. I-Lab_value
8 I-Lab_value
× I-Lab_value
109 I-Lab_value
/ I-Lab_value
L E-Lab_value
,	O
platelets S-Diagnostic_procedure
585 B-Lab_value
× I-Lab_value
109 I-Lab_value
/ I-Lab_value
L E-Lab_value
,	O
C B-Diagnostic_procedure
- I-Diagnostic_procedure
reactive I-Diagnostic_procedure
protein E-Diagnostic_procedure
37 B-Lab_value
. I-Lab_value
7 I-Lab_value
mg I-Lab_value
/ I-Lab_value
L E-Lab_value
and	O
erythrocyte B-Diagnostic_procedure
sedimentation I-Diagnostic_procedure
rate E-Diagnostic_procedure
69 B-Lab_value
mm I-Lab_value
/ I-Lab_value
hr E-Lab_value
.	O

Urea S-Diagnostic_procedure
and	O
electrolytes S-Diagnostic_procedure
,	O
complement S-Diagnostic_procedure
,	O
urine B-Diagnostic_procedure
analysis E-Diagnostic_procedure
and	O
microscopy S-Diagnostic_procedure
were	O
normal S-Lab_value
.	O

Rheumatoid B-Diagnostic_procedure
factor E-Diagnostic_procedure
,	O
antinuclear S-Detailed_description
and	O
antineutrophil S-Detailed_description
cytoplasmic B-Diagnostic_procedure
antibodies E-Diagnostic_procedure
,	O
cryoglobulins S-Diagnostic_procedure
and	O
Hepatitis B-Diagnostic_procedure
B I-Diagnostic_procedure
and I-Diagnostic_procedure
C I-Diagnostic_procedure
serology E-Diagnostic_procedure
were	O
negative S-Lab_value
.	O

Transthoracic S-Biological_structure
echocardiogram S-Diagnostic_procedure
showed	O
no B-Sign_symptom
signs I-Sign_symptom
of I-Sign_symptom
endocarditis E-Sign_symptom
,	O
and	O
multiple B-Diagnostic_procedure
blood I-Diagnostic_procedure
cultures E-Diagnostic_procedure
were	O
sterile S-Lab_value
.	O

A	O
skin S-Biological_structure
biopsy S-Diagnostic_procedure
from	O
the	O
ankle	O
revealed	O
a	O
perivascular B-Biological_structure
lymphohistiocytic I-Biological_structure
infiltrate E-Biological_structure
with	O
prominent	O
neutrophils S-Biological_structure
and	O
associated	O
fibrinoid S-Detailed_description
necrosis S-Sign_symptom
of	O
vessels S-Biological_structure
consistent	O
with	O
`	O
leukocytoclastic S-Detailed_description
`	O
vasculitis S-Disease_disorder
.	O

He	O
was	O
commenced	O
on	O
60 B-Dosage
mg E-Dosage
prednisolone S-Medication
per B-Dosage
day E-Dosage
leading	O
to	O
prompt S-Detailed_description
and	O
complete S-Detailed_description
resolution B-Sign_symptom
of I-Sign_symptom
all I-Sign_symptom
features E-Sign_symptom
.	O

The	O
dose	O
of	O
prednisolone S-Medication
was	O
rapidly	O
tapered	O
over B-Duration
the I-Duration
course I-Duration
of I-Duration
one I-Duration
month E-Duration
by	O
the	O
patient	O
,	O
faster	O
than	O
advised	O
but	O
without B-Sign_symptom
any I-Sign_symptom
recurrence E-Sign_symptom
over B-Duration
the I-Duration
following I-Duration
3 I-Duration
years E-Duration
.	O

-DOCSTART- -X- -X- -X- O

A	O
69 B-Age
- I-Age
year I-Age
- I-Age
old E-Age
woman	O
with	O
a	O
history	O
of	O
hypertension S-Disease_disorder
presented	O
with	O
a	O
generalized B-Detailed_description
petechial E-Detailed_description
rash S-Sign_symptom
and	O
shortness B-Sign_symptom
of I-Sign_symptom
breath E-Sign_symptom
of	O
3 B-Duration
days I-Duration
duration E-Duration
.	O

The	O
rash	O
was	O
nonpruritic S-Detailed_description
,	O
painless S-Detailed_description
,	O
and	O
started	O
at	O
the	O
thighs S-Biological_structure
,	O
but	O
rapidly	O
disseminated	O
to	O
the	O
rest B-Biological_structure
of I-Biological_structure
the I-Biological_structure
body E-Biological_structure
.	O

She	O
had	O
progressive S-Detailed_description
dyspnea S-Sign_symptom
on	O
exertion S-Detailed_description
,	O
with	O
a	O
significant	O
decrease S-Lab_value
in	O
exercise B-Diagnostic_procedure
tolerance E-Diagnostic_procedure
.	O

She	O
denied	O
fever S-Sign_symptom
,	O
headache S-Sign_symptom
,	O
dizziness S-Sign_symptom
,	O
hemoptysis S-Sign_symptom
,	O
or	O
bleeding S-Sign_symptom
from	O
anywhere S-Biological_structure
.	O

There	O
was	O
no	O
history	O
of	O
new	O
drug	O
use	O
,	O
unusual B-Activity
food I-Activity
intake E-Activity
,	O
contact	O
with	O
any	O
sick	O
persons	O
,	O
or	O
recent	O
travel S-Activity
.	O

Her	O
only	O
medication	O
was	O
enalapril S-Medication
,	O
which	O
she	O
had	O
been	O
taking	O
for	O
several B-Duration
years E-Duration
.	O

The	O
patient	O
denied	O
any	O
use	O
of	O
recreational B-Activity
drugs E-Activity
,	O
tobacco S-Activity
,	O
or	O
alcohol S-Activity
.	O

On	O
admission	O
,	O
she	O
was	O
afebrile S-Sign_symptom
,	O
normotensive S-Sign_symptom
with	O
mild S-Severity
tachypnea S-Sign_symptom
(	O
respiratory B-Diagnostic_procedure
rate E-Diagnostic_procedure
of	O
22 B-Lab_value
breaths I-Lab_value
per I-Lab_value
minute E-Lab_value
)	O
.	O

Physical B-Diagnostic_procedure
examination E-Diagnostic_procedure
revealed	O
scattered	O
petechial S-Detailed_description
rash S-Sign_symptom
,	O
more	O
prominent	O
in	O
lower B-Biological_structure
extremities E-Biological_structure
,	O
nonpalpable S-Detailed_description
and	O
nonblanching S-Detailed_description
.	O

Chest B-Diagnostic_procedure
auscultation E-Diagnostic_procedure
revealed	O
coarse S-Detailed_description
crackles S-Sign_symptom
bilaterally S-Detailed_description
.	O

Cardiovascular S-Biological_structure
,	O
abdominal S-Biological_structure
,	O
and	O
neurological S-Detailed_description
examinations S-Diagnostic_procedure
were	O
normal S-Lab_value
.	O

There	O
was	O
no	O
palpable	O
lymphadenopathy S-Sign_symptom
or	O
visceromegaly S-Sign_symptom
.	O

Laboratory B-Diagnostic_procedure
examination E-Diagnostic_procedure
revealed	O
thrombocytopenia S-Sign_symptom
(	O
platelets S-Diagnostic_procedure
7000 B-Lab_value
/ I-Lab_value
μL E-Lab_value
)	O
,	O
anemia S-Sign_symptom
(	O
hemoglobin S-Diagnostic_procedure
10 B-Lab_value
. I-Lab_value
8 I-Lab_value
mg I-Lab_value
/ I-Lab_value
dL E-Lab_value
and	O
hematocrit S-Diagnostic_procedure
34 B-Lab_value
% E-Lab_value
)	O
,	O
and	O
leukocytosis S-Sign_symptom
(	O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cells E-Diagnostic_procedure
[	O
WBCs S-Diagnostic_procedure
]	O
11,600 B-Lab_value
/ I-Lab_value
μL E-Lab_value
)	O
.	O

The	O
coagulation B-Diagnostic_procedure
profile E-Diagnostic_procedure
was	O
normal S-Lab_value
,	O
which	O
excluded	O
disseminated B-Disease_disorder
intravascular I-Disease_disorder
coagulation E-Disease_disorder
.	O

Arterial B-Diagnostic_procedure
blood I-Diagnostic_procedure
gas E-Diagnostic_procedure
on	O
ambient B-Detailed_description
air E-Detailed_description
revealed	O
a	O
partial B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of I-Diagnostic_procedure
oxygen E-Diagnostic_procedure
(	O
PaO2 S-Diagnostic_procedure
)	O
of	O
64 B-Lab_value
Torr E-Lab_value
,	O
a	O
partial B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of I-Diagnostic_procedure
carbon I-Diagnostic_procedure
dioxide E-Diagnostic_procedure
(	O
PaCO2 S-Diagnostic_procedure
)	O
of	O
37 B-Lab_value
Torr E-Lab_value
(	O
pH S-Diagnostic_procedure
7 B-Lab_value
. I-Lab_value
45 E-Lab_value
)	O
,	O
and	O
an	O
increased S-Lab_value
alveolar B-Diagnostic_procedure
- I-Diagnostic_procedure
arterial I-Diagnostic_procedure
gradient E-Diagnostic_procedure
(	O
44 B-Lab_value
Torr E-Lab_value
)	O
.	O

Diffuse S-Detailed_description
airspace B-Sign_symptom
consolidation E-Sign_symptom
was	O
found	O
on	O
chest S-Biological_structure
roentgenogram S-Diagnostic_procedure
(	O
Fig	O
.	O
1A	O
)	O
.	O

Computed B-Diagnostic_procedure
tomography E-Diagnostic_procedure
(	O
CT S-Diagnostic_procedure
)	O
of	O
the	O
chest S-Biological_structure
showed	O
diffuse S-Detailed_description
ground B-Texture
glass E-Texture
alveolar S-Biological_structure
opacities S-Sign_symptom
and	O
patchy S-Detailed_description
infiltrates S-Sign_symptom
(	O
Fig	O
.	O
1B	O
,	O
C	O
)	O
.	O

She	O
was	O
started	O
on	O
broad B-Detailed_description
- I-Detailed_description
spectrum E-Detailed_description
antibiotics S-Medication
and	O
received	O
intravenous	O
steroids S-Medication
.	O

Peripheral B-Diagnostic_procedure
smear E-Diagnostic_procedure
showed	O
giant B-Sign_symptom
platelets E-Sign_symptom
and	O
occasional B-Detailed_description
small E-Detailed_description
platelet B-Sign_symptom
clumps E-Sign_symptom
,	O
with	O
no	O
schistocytes S-Sign_symptom
.	O

A	O
flexible B-Diagnostic_procedure
fiber I-Diagnostic_procedure
- I-Diagnostic_procedure
optic I-Diagnostic_procedure
bronchoscopy E-Diagnostic_procedure
(	O
FFB S-Diagnostic_procedure
)	O
showed	O
normal S-Lab_value
mucosa S-Diagnostic_procedure
with	O
no	O
endobronchial S-Biological_structure
lesions S-Sign_symptom
(	O
Fig	O
.	O
2A	O
)	O
.	O

Serial	O
aliquots	O
of	O
BAL B-Diagnostic_procedure
fluid E-Diagnostic_procedure
(	O
BALF S-Diagnostic_procedure
)	O
turned	O
more	O
hemorrhagic S-Sign_symptom
,	O
confirming	O
the	O
bronchoscopic	O
diagnosis	O
of	O
DAH S-Disease_disorder
(	O
Fig	O
.	O
2B	O
)	O
.	O

Cytology S-Diagnostic_procedure
of	O
BALF	O
showed	O
a	O
substantial	O
amount	O
of	O
hemosiderin B-Detailed_description
- I-Detailed_description
laden E-Detailed_description
macrophages S-Sign_symptom
,	O
further	O
supporting	O
the	O
diagnosis	O
.	O

All	O
BALF	O
cultures S-Diagnostic_procedure
and	O
gram B-Diagnostic_procedure
stains E-Diagnostic_procedure
were	O
negative S-Lab_value
.	O

The	O
patient	O
remained	O
with	O
severe S-Severity
thrombocytopenia S-Sign_symptom
and	O
hypoxia S-Sign_symptom
despite	O
steroids S-Medication
and	O
platelets B-Medication
transfusion E-Medication
.	O

High B-Dosage
doses E-Dosage
of	O
pulse	O
steroids S-Medication
and	O
intravenous	O
immunoglobulins S-Medication
(	O
IVIGs	O
)	O
were	O
added	O
with	O
clinico B-Detailed_description
- I-Detailed_description
radiological E-Detailed_description
improvement S-Sign_symptom
.	O

A	O
bone B-Diagnostic_procedure
marrow I-Diagnostic_procedure
aspirate E-Diagnostic_procedure
was	O
morphologically B-Lab_value
normal E-Lab_value
.	O

Additional	O
laboratory B-Diagnostic_procedure
studies E-Diagnostic_procedure
failed B-Lab_value
to I-Lab_value
reveal I-Lab_value
an I-Lab_value
etiology E-Lab_value
for	O
secondary	O
thrombocytopenia S-Sign_symptom
(	O
Table	O
1	O
)	O
,	O
supporting	O
the	O
diagnosis	O
of	O
ITP S-Disease_disorder
.	O

Steroids S-Medication
were	O
gradually	O
tapered	O
.	O

Repeat	O
chest S-Biological_structure
radiograph S-Diagnostic_procedure
showed	O
almost	O
complete	O
resolution	O
of	O
bilateral S-Detailed_description
infiltrates S-Sign_symptom
(	O
Fig	O
.	O
3	O
)	O
.	O

Platelet B-Diagnostic_procedure
count E-Diagnostic_procedure
returned	O
to	O
normal S-Lab_value
by	O
week	O
10	O
after	O
admission	O
without	O
any	O
additional B-Therapeutic_procedure
therapies E-Therapeutic_procedure
(	O
Fig	O
.	O
4	O
)	O
.	O

